Entities

Lance Matthews is listed by DTCP as Partner in its Growth directory. Leads North American technology investing, focusing on AI infrastructure, cloud systems and cybersecurity. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Lara van Valen is listed by DTCP as Executive Assistant in its Platform directory. Provides executive assistance after five years of office-management and executive-assistance experience at an Australian property business. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Laura Müller is listed by DTCP as Executive Assistant in its Platform directory. Provides executive assistance to Thomas Preuß and Michael Rager, with earlier corporate administration and hospitality experience. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Lodovico Carini is listed by DTCP as Associate in its Growth directory. Focuses on European growth software investments, including the UK, Ireland and France; previously invested at Target Global and worked in N26 strategy. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Maja Mikolajczyk is listed by DTCP as Manager Capital Formation Real Assets in its Infra directory. Works on real-assets capital formation after corporate-banking experience at Citi and markets work at Goldman Sachs. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Malte Koch is listed by DTCP as Manager Finance in its Platform directory. Works in finance after building a finance team at venture-fund administrator Brightpoint Fund Services. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Maria Escarti is listed by DTCP as Head of Valencia Office & Global Admin Team Lead in its Platform directory. Leads the Valencia office and global administration; previously led EIT Health’s deep-tech venture-building programme and other startup initiatives. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Maria Stepanova is listed by DTCP as Director Corporate & Investment Controlling in its Platform directory. Leads corporate and investment controlling after finance-operations responsibilities at eDreams ODIGEO. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Marianne Karlsen is listed by DTCP as Head of Strategy Office & Operations in its Platform directory. Leads strategy and operations across HR, administration, technology and marketing, including the platform’s digital and AI work. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Martin Klima is listed by DTCP as Chief Financial Officer in its Platform directory. Leads finance and is named in the legal notice as a managing director; previously held finance, strategy and transaction roles at Innogy, RWE and Siemens. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Michael Rager is listed by DTCP as Partner in its Growth directory. Sources and develops European software investments after Bauer Venture Partners and Otto Group strategy work. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Michal Filipczak is listed by DTCP as Associate in its Infra directory. Works on infrastructure transactions and portfolio oversight; previously advised technology and telecom deals at Credit Suisse in London. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Mihal Rahman is listed by DTCP as Manager Finance in its Platform directory. Works in finance, with earlier fund audit work in Luxembourg and KPMG audit responsibilities in Germany. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Nicolas Rutherford is listed by DTCP as Associate in its Infra directory. Works in infrastructure investing after European technology and telecom transaction work at Lazard in London. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Ole Aguirre is listed by DTCP as Partner in its Defence directory. Leads defence investing and portfolio strategy, drawing on commercial defence work at Teledyne FLIR and earlier military service in Norway. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Philipp von Bismarck is listed by DTCP as Managing Partner in its Infra directory. Serves on the infrastructure investment committee and previously worked as a transaction lawyer at Wendelstein, Hengeler Mueller and Wachtell Lipton. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Selina Thoma is listed by DTCP as Senior Manager ESG in its Platform directory. Works on ESG after sustainability-engineering experience at Amazon involving electric mobility and energy efficiency. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Shu Konakahara is identified as an AbbVie Ventures scientist in residence in Tokyo in the official2025 impact report. Current operational tenure is not confirmed by the newer website roster; further biography is unpublished in the reviewed report.

Stefan Uhlitzsch is listed by DTCP as Head of Finance in its Platform directory. Leads finance from Luxembourg after establishing the finance team at J.P. Morgan Mobility Payments Solutions and earlier PwC audit work. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Stephan Grillmaier is listed by DTCP as Head of Capital Formation Real Assets in its Infra directory. Leads real-assets capital formation after heading investor relations and co-investments at Arcus Infrastructure Partners. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Susana Vilela is listed by DTCP as Office Manager in its Platform directory. Manages the Hamburg office after reception work in chemicals trading and earlier hospitality entrepreneurship. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Susie Meier is listed by DTCP as Managing Director in its Growth directory. Focuses on European enterprise software and fintech investments, with previous venture-investing and fundraising responsibilities at HV Capital. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Thomas Preuß is listed by DTCP as Managing Partner in its Growth directory. Helped establish DTCP’s growth business in2015, serves on growth-fund investment committees and leads the defence strategy’s investment function. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Tim Hofmann is listed by DTCP as Managing Director in its Infra directory. Works in infrastructure investments and portfolio boards, with prior investment-banking experience at Greenhill. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Vicente Vento is listed by DTCP as Founder & CEO, Managing Partner in its Infra directory. Founded the platform and oversees investment strategy and portfolio development; previously led Deutsche Telekom’s M&A work. Legal notice names Vicente Vento Bosch as managing director. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Virginia García is listed by DTCP as Manager Marketing & Operations in its Platform directory. Works in marketing and operations in Valencia, with previous investment-promotion and public-affairs experience at Invest in Valencia. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Waldemar Maurer is listed by DTCP as Partner in its Infra directory. Serves on the infrastructure investment committee and portfolio boards, focusing on telecom, data centres and towers. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Yan Bieger is listed by DTCP as Vice President in its Growth directory. Works in the US growth team and previously developed data products as a consultant in Brazil; trained in mechanical engineering at UFSC. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Zahl Limbuwala is listed by DTCP as Operating Partner in its Infra directory. Supports data-centre investments and portfolio operations, drawing on leadership at AtlasEdge and Romonet and published maincubes and GreenScale board capacities. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Zohal Aslami is listed by DTCP as Manager Finance in its Platform directory. Her finance experience includes Mazars and investor-facing finance and controlling in Hamburg shipping. Source scope: current own directory; appointment day and personal investment subscriptions are not inferred.

Albert Lai is published in AbbVie’s venture team as Senior Venture Partner, AbbVie Ventures. Cancer geneticist and biochemist with oncology-discovery and external-innovation leadership.

Alberto Colzi is AbbVie’s senior vice president, commercial strategy and transformation. He works on commercial strategy, international growth and AI-enabled commercial capabilities, following regional pharmaceutical leadership.

Azita Saleki is AbbVie’s executive vice president, chief operations officer. She leads pharmaceutical operations, quality, engineering and supply-chain functions, with pharmacy degrees from the University of Wisconsin.

Brett J. Hart is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: President of United Airlines. This external background is distinct from the AbbVie directorship.

Christian Schubert is published in AbbVie’s venture team as Vice President, Global Head of AbbVie Ventures. Genetics, neurobiology and biochemistry background, with company creation, venture and pharmaceutical partnering experience.

Christina Vorvis is published in AbbVie’s venture team as Director, AbbVie Ventures. Cancer biologist and early-stage therapeutics investor with experience at Amgen, OrbiMed and Back Bay.

Claire Leurent is published in AbbVie’s venture team as Managing Director, AbbVie Ventures. Molecular/cellular biologist with clinical development and venture investing experience at Samsung Ventures and JJDC.

Dave Purdue is AbbVie’s senior vice president, corporate controller. He leads global financial planning/reporting and previously held finance roles at Abbott and PwC.

Demetris D. Crum is AbbVie’s executive vice president, chief human resources officer. His career includes human-resources leadership at AbbVie, Kraft Foods and Pepsi, and labor-relations studies at Michigan State.

Doug Faunce is published in AbbVie’s venture team as Executive Director, AbbVie Ventures. Immunologist with pharmaceutical search/evaluation, partnering and drug-development experience.

Edward J. Rapp is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former Caterpillar executive. This external background is distinct from the AbbVie directorship.

Elizabeth Shea is AbbVie’s senior vice president, investor relations. She manages investor communications and relationships, with prior corporate communications and public-affairs experience.

Frederick H. Waddell is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former Northern Trust chairman/CEO. This external background is distinct from the AbbVie directorship.

Jag Dosanjh is AbbVie’s senior vice president, abbvie and president, immunology. He leads the immunology business and previously managed neuroscience/eye-care portfolios and roles at GSK.

Jason Smith is AbbVie’s senior vice president, abbvie and president, neuroscience. He leads the U.S. neuroscience commercial business and global neuroscience strategy, with prior European operations and Novartis experience.

Jeffrey R. Stewart is AbbVie’s executive vice president, chief commercial officer. He leads global commercial operations and developed his pharmaceutical career at TAP and Abbott.

Jennifer L. Davis is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former healthcare chief executive at Procter & Gamble. This external background is distinct from the AbbVie directorship.

Jeremy Edmunds is published in AbbVie’s venture team as Senior Venture Partner, AbbVie Ventures. Medicinal chemist with decades of small-molecule discovery and discovery-team leadership.

Jérôme Bouyer is AbbVie’s senior vice president, abbvie and president, international therapeutics. He leads international commercial operations, following country and regional leadership at Abbott/AbbVie and Novartis.

Joachim Vogt is published in AbbVie’s venture team as Director, AbbVie Ventures. Chemist with protein-crystallography training and pharmaceutical research/business-development experience.

Keith Hamel is published in AbbVie’s venture team as Scientist in Residence; Director / Senior Principal Research Scientist, Oncology Discovery. Pharmacology leader in oncology/immunology who supports venture scientific evaluation and company mentorship.

Latif Akintade is AbbVie’s senior vice president, medical affairs + health impact. His work spans medical evidence, market access and medicines value; prior roles include Pfizer and Eisai.

Laura Pedroza is published in AbbVie’s venture team as Associate Director, AbbVie Ventures Europe. Protein-biochemistry researcher and investor previously with High-Tech Gründerfonds.

Linda Ray is AbbVie’s senior vice president, chief information officer. She leads company technology systems and data assets and previously held technology roles at Grainger.

Lori M. Reilly is AbbVie’s senior vice president, government affairs. She leads global government affairs, following advocacy and policy leadership at PhRMA and congressional legal work.

Melody B. Meyer is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former Chevron Asia Pacific executive. This external background is distinct from the AbbVie directorship.

Michael McPherson is published in AbbVie’s venture team as Scientist in Residence; Research Fellow. Drug-discovery scientist leading AbbVie’s antibody-drug-conjugate platform research. Presented under Scientists in Residence in the current venture directory.

Michael Rosenzweig is published in AbbVie’s venture team as Senior Venture Partner, AbbVie Ventures. Veterinarian/scientist with Merck discovery leadership and prior RA Capital and Capstan development experience.

Nicholas Donoghoe is AbbVie’s executive vice president, chief business and strategy officer. His responsibilities include corporate strategy, partnering and business technology; he holds a Johns Hopkins medical degree and previously worked at McKinsey.

Nicole Mowad-Nassar is AbbVie’s senior vice president, abbvie and president, global allergan aesthetics. She leads global aesthetic medicines and technologies and previously worked in commercial analytics, specialty products and Allergan integration.

Nisha Patel Burns is AbbVie’s senior vice president, abbvie and president, specialty and u.s. therapeutics operations. She leads specialty medicines and U.S. therapeutics operations, with engineering and business degrees from Northwestern.

Perry C. Siatis is AbbVie’s executive vice president, general counsel and secretary. He leads legal, ethics/compliance and government affairs, following IP litigation and pharmaceutical legal leadership.

Rebecca B. Roberts is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former Chevron Pipe Line president. This external background is distinct from the AbbVie directorship.

Robert A. Michael is AbbVie’s chairman of the board and chief executive officer. He previously served as AbbVie president/COO and CFO and has accounting training at Indiana University and an MBA from UCLA.

Roopal Thakkar is AbbVie’s executive vice president, research & development, chief scientific officer. He leads drug-development and scientific operations, with prior clinical-development, regulatory and chief-medical roles at Abbott/AbbVie.

Roxanne S. Austin is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: President of Austin Investment Advisors. This external background is distinct from the AbbVie directorship.

Scott T. Reents is AbbVie’s executive vice president, chief financial officer. He previously led tax and treasury at AbbVie and held finance roles at Abbott, Pfizer, Pharmacia and Deloitte.

Shann Yu is published in AbbVie’s venture team as Associate Director and Chief of Staff, AbbVie Ventures. Bioengineering/immunology background and experience in business development, analytics and strategic leadership.

Shawna Frazier is published in AbbVie’s venture team as Director, AbbVie Ventures. Biochemist/biophysicist with biotech investing, corporate strategy and founder experience in neurological and ocular medicines.

Simranjit Singh is published in AbbVie’s venture team as Associate Director, AbbVie Ventures. Cancer biologist previously at Nextech Ventures, Rezo Therapeutics and Arvinas, with a Duke doctorate.

Subhabrata Sanyal is published in AbbVie’s venture team as Senior Venture Partner, AbbVie Ventures. Neuroscience drug-discovery researcher, previously Calico translational-neuroscience head, Biogen investigator and Emory faculty.

Susan E. Quaggin is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Physician and medicine chair at Northwestern University. This external background is distinct from the AbbVie directorship.

Tadaatsu Naka is identified as an AbbVie Ventures scientist in residence in Tokyo in the official2025 impact report. Current operational tenure is not confirmed by the newer website roster; further biography is unpublished in the reviewed report.

Thomas C. Freyman is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former finance/administration executive at Abbott. This external background is distinct from the AbbVie directorship.

Thomas J. Falk is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Former chairman/CEO at Kimberly-Clark. This external background is distinct from the AbbVie directorship.

Tom Wu is published in AbbVie’s venture team as Head of AbbVie Ventures Asia Pacific. Molecular biology, bioinformatics and business-strategy background with pharmaceutical R&D and partnering experience.

Tracie Haas is AbbVie’s senior vice president, corporate affairs. She leads communications, reputation, philanthropy and patient-assistance programs, with prior commercial and foundation leadership.

William H.L. Burnside is a published member of AbbVie’s board of directors. The company’s current board directory identifies the professional background as: Retired senior executive at Boston Consulting Group. This external background is distinct from the AbbVie directorship.

Wulff-Erik von Borcke is AbbVie’s senior vice president, abbvie and president, oncology. He leads U.S. oncology commercial operations and global oncology strategy and previously led Pharmacyclics and global marketing.

W.N. "Bill" Wilkins is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Bill Rasmussen is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Eric Pitcher is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Tom Picone is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Tony Mendez is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Michael R. "Rich" Clifford is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Carl Bolch, Jr. is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Eugenia Brin is listed by the Michael J. Fox Foundation as Patient Council Legacy Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

M. Daniel Suwyn is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Margaret Sheehan is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Richie Rothenberg is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Hilton Mirels is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Soania Mathur is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Nicole Jarvis is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

David Iverson is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Karen Jaffe is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Bill Geist is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Cynthia Gray is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

David Eger is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Anne Cohn Donnelly, D.P.H. is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Steven D. DeWitte is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Quentin Dastugue is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Carey Christensen is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Christopher Chadbourne is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Ken Cater is listed by the Michael J. Fox Foundation as Patient Council Emeritus Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Lisa Volenec is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Molly R. Stern is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Allie Signorelli is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Israel Robledo is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

John P. Seibyl is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Bryan M. Roberts is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Claudia Revilla is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Donna Rajkovic is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Gary Rafaloff is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Matthew Peck is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Julie Ocko is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

David Nutter is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Patrick Morrissey is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Curtis Miner is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Rebecca Miller is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Sheryl Lowenhar is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment. Sheryl Lowenhar is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Wanda Kim Lilley is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Kevin Kwok, PharmD is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Sebastian Krys is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Donna Krenicki is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Richard Huckabee is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Yvonne Jackson is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Kathy Holden is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Ethan Henderson is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Larry Gifford is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Michael S. Fitts is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Hadley Ferguson is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Peter DiBiaso is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

María L. De León is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment. Maria De Leon is listed in Synapticure’s current public Patient & Caregiving Advisors directory. This is a source-qualified advisory affiliation rather than clinical employment or evidence of a personal investment.

Fiona Davis is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Mike DeBartolo is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Denise Coley is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Jimmy Choi is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Leonard Chandler is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Bill Bucklew is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Derek Bandeen is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Matt Ackerman is listed by the Michael J. Fox Foundation as Patient Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Bret Parker is listed by the Michael J. Fox Foundation as Co-Chair, Patient Council. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Lynn Hagerbrant is listed by the Michael J. Fox Foundation as Co-Chair, Patient Council. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Andrew S. Grove is listed by the Michael J. Fox Foundation as Founder’s Council Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

David Golub is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Donna Shalala is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment. Donna Shalala appears in Primetime Partners' published external adviser roster. The firm associates this person with Former Congresswoman (FL), U.S. Secretary of HHS. This records the named adviser affiliation, with no operating staff role or personal investment inferred. The outside-employer title is the firm's published descriptor; its present-day tenure was not independently established in this audit.

Edwin A. Levy is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Jeffrey Katzenberg is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

John Griffin is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Katie Hood is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Lily Safra is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Morton M. Kondracke is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Nora McAniff is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Albert B. Glickman is listed by the Michael J. Fox Foundation as Founder’s Council Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Amar Kuchinad is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Anne-Cecilie Engell Speyer is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Ari Richter is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Barry Malkin is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Bonnie Strauss is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Carolyn Schenker is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Colin Masson is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Curtis Schenker is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Douglas I. Ostrover is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Fred G. Weiss is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

George "Sonny" Whelen is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

George Stephanopoulos is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Hartley T. Richardson is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Jack Quinn is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Lisa A. Piazza is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Lonnie Ali is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Marc S. Lipschultz is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Muhammad Ali is listed by the Michael J. Fox Foundation as Founder’s Council Member (historical / deceased). The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Ofer Nemirovsky is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Pamela Mirels is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Peter Zaffino is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Richard J. Schnall is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Ryan Reynolds is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Steven A. Cohen is listed by the Michael J. Fox Foundation as Founder’s Council Member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Tracy Pollan is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Woody Shackleton is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Akbar Gbajabiamila is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Alex Krys is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Anne M. Holloway is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

David Einhorn is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

David Glickman is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Edward Kalikow is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Gabe Gelman is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Jeff Keefer is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Karen Finerman is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Melanie Isbill is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Nelle Fortenberry is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Richard Fitzgerald is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

William R. Geist is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Donny Deutsch is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Andrew Creighton is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Barry J. Cohen is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

John S. Daly is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Mark Booth is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Susan Bilotta is listed by the Michael J. Fox Foundation as Board of Directors member. The published foundation biography describes this governance or volunteer affiliation; it is not an assertion of operating employment or a personal investment.

Dietske Devillé is listed by Korys as HR Responsible. She handles human-resources responsibilities in the current public corporate team.

A former Alamar director affiliated with Sherpa Healthcare Partners, identified in the issuer’s IPO related-party financing disclosures. Also known as Darren Cai, he is not listed on the current Alamar board. The historical director attribution is retained without claiming a current role or attributing the institutional buyer’s capital to him personally. Daqing Cai, also known as Darren Cai, is a managing partner and founder of Sherpa Healthcare Partners. He previously served as a Legend Capital managing director and co-led its healthcare team, focusing on biotechnology, diagnostics, medical devices and medical services. He holds a UC Berkeley PhD, Yale MBA and USTC bachelor’s degree. Earlier investments listed in his biography are personal professional history rather than automatically Sherpa fund checks.

Sabrina Schoriels is listed by Korys as Management Assistant. She joined in 2026 to provide management support to Stefaan Vandamme and coordinate daily operations.

Emanuelle Moreau is listed by Korys as Management Assistant. She supports Dries Crevits and coordinates operations, events and projects. She joined in 2024 after program-management and healthcare consulting work at IBM.

A former Alamar director affiliated with Qiming investment entities, identified in the issuer’s IPO related-party financing disclosures. The April 2026 prospectus calls him a former director; he is not on the current October 2026 board roster. The record preserves this historical investment-governance connection without claiming a current Alamar role or a personal cash investment. William Hu is Managing Partner at Qiming Venture Partners. Co-leads Qiming’s healthcare investing and joined the firm in 2006. His work covers medical devices, biopharmaceuticals, diagnostics and healthcare services. He studied medicine at Shanghai Medical University and earned an MBA at ENPC’s Shanghai campus. Historical Alamar board service is recorded separately from his current manager position.

Tine Bigaré is listed by Korys as Management Assistant & Press Relations. She coordinates management support, events and press relations. Her biography retains an older partner reference to Griet Aerts, while the current directory now identifies Griet as advisor; no current partner role is inferred from that stale sentence.

An Alamar director from February 2024 and a former Sands Capital life-sciences managing partner. Earlier he led Enzymatics, founded Stemgent and was president of Upstate. He studied chemical engineering at Surrey and earned an MBA at the University of Virginia. Sands Capital’s July 10, 2026 memorial confirms his death; the source does not establish an exact death date. This role is historical rather than current.

Tineke Demey is listed by Korys as Paralegal. She handles contracts, corporate housekeeping and legal or compliance support. Her earlier work included over a decade of M&A and finance paralegal experience at Bekaert.

Ben van Reepingen is listed by Korys as Controller. He supports reporting and daily finance processes after audit work at KPMG and management studies at VUB.

Alamar director since January 2026 and lead independent director from its IPO in April 2026. An operating partner at Ampersand Capital Partners, he previously led Affymetrix, Dionex and Panomics. He holds microbiology degrees from Illinois and Indiana and a doctorate in molecular and cellular biology from Indiana University.

Helga De Coster is listed by Korys as Accountant. She supports tax, accounting compliance and group accounting procedures. Her tenure began in 2000 at the first investment company; this does not imply the current brand existed then.

Known professionally as Bob Ragusa, an Alamar director publicly announced October 5, 2026. Former GRAIL CEO, he retired from that role June 1, 2026 and remains an advisor during the transition. Earlier he was Illumina COO and held operations positions at Accuray, Bloom Energy, Affymetrix and Applied Biosystems. His current Alamar director role is verified independently in the governance directory.

Tina Deneef is listed by Korys as Senior Finance Manager. She manages finance within the corporate team after transaction-diligence consulting at EY. She joined in 2020 and studied commercial engineering.

Fabienne Van de Keere is listed by Korys as Senior Advisor. She advises the liquid-investment team on listed life-sciences companies after research on HIV and autoimmune disease in Belgium and the US. Her qualifications include a doctorate in biology.

Known as Nick Naclerio, an Alamar director since May 2020 and founding partner of Illumina Ventures. He previously led corporate and venture development at Illumina and co-founded Quanterix, after executive roles at True Materials and ParAllele BioScience. He studied at Duke and earned an electrical engineering doctorate at the University of Maryland. Fund beneficial ownership is distinct from a personal cash investment. IlluminaVentures currentownpublished affiliation: Founding Partner. Nick is the Founding Partner of Illumina Ventures. His passion is building companies at the intersection of technology and human health. Prior to joining the fund, he served as SVP, Corporate & Venture Development for Illumina Inc., where he was responsible for strategic planning, business development, licensing, venture investing and acquisitions. In six years, Nick and his team completed ten acquisitions, more than a dozen venture investments, and a multitude of other transactions including the formation of Helix and GRAIL and the creation of a global NIPT patent pool. Nick also served as the founding General Manager of Illumina’s Enterprise Informatics Business Unit. Before joining Illumina Inc., Nick co-founded and was the Executive Chairman of the diagnostics company Quanterix. Previously he was Executive Chairman of True Materials and CEO of ParAllele BioScience, life science tools firms that were both acquired by Affymetrix. Nick got his start in venture investing at Motorola where he led the life science investment team and served on the boards of the SNP Consortium, Genometrix, Clinical Microsensors, and Orchid Bioscience. He founded and led Motorola Life Sciences, an early microarray company that was acquired by GE. He also held leadership positions at DARPA and served on the board of SEMATCH. Nick received a B.S. in Engineering from Duke University, was a Winston Churchill Scholar at Cambridge University, and earned a Ph.D. in Electrical Engineering from the University of Maryland. Portfolio involvement is institutionalboard/support context, not personalcash attribution.

Thomas Leclercq is listed by Korys as Investment Manager. He supports the sustainable multi-asset fund and broader liquid portfolio, combining financial analysis with the platform’s sustainability objectives.

Gert Ryckmans is listed by Korys as Senior Investment Manager. He selects and monitors Conscious Consumer exposures within the liquid portfolio. He joined in 2012 after asset management and banking experience and holds the CFA designation.

Pablo Queriat is listed by Korys as Senior Investment Manager. He invests in listed Energy Transition businesses. He joined in 2016 after institutional portfolio management at Degroof Petercam and holds engineering and energy-policy doctoral qualifications.

Alamar director since January 2026 and executive vice president/CFO at Veracyte. She previously served as CFO of Outset Medical and held senior finance and investor-relations positions at Illumina, Myriad Genetics and Life Technologies. She studied biology at John Carroll University and earned an MBA at Cornell.

Appointed Alamar chief people officer in the issuer’s October 5, 2026 leadership announcement. She previously led people functions at Guardant Health, RMS and Outset Medical, with earlier experience at VeriSign, webMethods and Juniper Networks. Her omission from the older executive directory does not negate the later appointment announcement.

Jérôme Thomas is listed by Korys as Investment Director. He directs the listed-equity team, covering the platform’s three thematic ecosystems. He joined in 2009 after M&A analysis at Fortis and holds the CFA designation.

Alamar’s current executive responsible for artificial intelligence and strategic initiatives, named in the company’s leadership directory and June 2026 investor presentation. His role links the company’s protein measurement platform with its developing analytical and strategic programmes. The directory does not provide an appointment date or a personal investment disclosure.

Daniel Leuthardt is listed by Korys as Investment Director. He leads the Luxembourg liquid-investment team and manages the sustainable multi-asset strategy. He joined in April2015 after treasury and pension-investment work at Clariant and holds the CFA designation.

Alamar’s published sales leader and host of company-sponsored neuroscience biomarker discussions. The company lists him in its January and March 2026 Alzheimer research webinars alongside external scientific experts. Those research presentations do not establish diagnostic approval of the platform.

Matthijs Vanden Auweele is listed by Korys as Junior Investment Analyst. He assesses life-sciences businesses after interning at Korys. His studies combine bioscience engineering with biotechnology and medical-technology entrepreneurship.

Alamar’s current marketing executive and an author of the company’s published discussions of protein detection sensitivity and biomarker research. Her work communicates the company’s research-use proteomics platform and its applications; the company’s July 2023 and July 2024 articles identify her professional participation.

David Devigne is listed by Korys as Investment Director. He directs life-sciences direct and fund investing and advises the separately managed OMX Europe fund. Earlier work includes PMV and immunology research strategy at UCB; his education spans pharmaceutical science and entrepreneurial finance.

Eva Van Overmeire is listed by Korys as Senior Investment Manager. She supports life-sciences investing after healthcare consulting at McKinsey and immunology strategy at UCB. She joined in August2022 and holds bioengineering and immunology doctoral qualifications.

Alamar general counsel, publicly announced in October 2026. His legal leadership background includes general counsel at Outset Medical and senior legal positions at Omnicell. The current Alamar executive directory independently lists him as general counsel.

Ides Vandorpe is listed by Korys as Investment Analyst. His Energy Transition investing draws on earlier energy-consulting experience at Roland Berger and finance or investment internships. He studied business engineering and financial management.

An Alamar co-founder and technology leader whom the issuer identifies as a structural biologist with antibody engineering expertise. His current vice-president role concerns development of the company’s ultrasensitive proteomics technologies. The current published directory confirms his continuing role; an appointment day is not disclosed.

François de Decker is listed by Korys as Investment Analyst. He analyzes Energy Transition opportunities and supports transaction execution after M&A work at Daikin’s EMEA headquarters.

Karel Van Cleemput is listed by Korys as Senior Investment Manager. He focuses on venture and private-equity investments in energy and mobility. He joined in 2019 after investment banking at KBC Securities.

Quentin Dupont is listed by Korys as Senior Investment Manager. He originates and executes Energy Transition direct and fund investments. Before joining in 2022 he advised family businesses and private-equity clients on M&A at Deloitte.

Known as Steve Williams, this physician-scientist joined Alamar as CSO in January 2026. Previously CMO at Standard BioTools and SomaLogic, he developed machine-learning models for large-scale proteomics and earlier led clinical technology work at Pfizer. He trained in medicine and physiology in London and radiology in Newcastle. Prior employers’ regulated tests do not establish clearance of Alamar products.

Brieuc de Hults is listed by Korys as Investment Director. He leads investments in technologies that enable renewable-energy adoption. He joined in 2012 after portfolio-management roles at Henderson and Fortis.

Alamar’s published chief technology officer and a molecular detection technology researcher. The issuer identifies him as a co-inventor of RNAscope alongside Yuling Luo, applying molecular assay development expertise to the company’s high-sensitivity protein detection platform. His appointment is verified by the current executive directory; no exact start date is inferred.

Frederik Bauwens is listed by Korys as Investment Director. He focuses on renewable-energy infrastructure investing within the Energy Transition team and has completed executive corporate-finance training at Vlerick.

Known professionally as Steve Chen, this Alamar co-founder previously co-founded Advanced Cell Diagnostics as COO and Panomics as CTO. Before industry he researched optical sensors and instrumentation at the University of Maryland. He studied precision instrumentation at USTC and electronic engineering at the University of London; he is distinct from other entrepreneurs named Steve Chen.

Appointed Alamar CFO in October 2025 after serving as CFO at Cellares and 10x Genomics. His earlier finance career included Tesla, Apple and Johnson & Johnson, following nine years as a US Navy aviator. He studied systems engineering at the US Naval Academy and earned an MBA at the University of San Diego.

Vincent Caudron is listed by Korys as Investment Manager. He supports Conscious Consumer investing following M&A advisory and valuation work at KPMG. He studied business engineering at KU Leuven.

Known professionally as Tod White, he became Alamar president in October 2025 after serving as CFO and chief business officer from March 2021. He founded investment bank EMA and previously served as general counsel and vice president at Packard BioScience. His education includes Hamilton College and a law degree from the University of Michigan.

Katti Van Oosterwijck is listed by Korys as Senior Investment Manager. She originates and executes Conscious Consumer direct and fund investments and represents the platform on company boards. She joined in 2019 following M&A legal practice.

Wouter Verstringe is listed by Korys as Senior Investment Manager. He joined the Conscious Consumer team in 2025 after establishing and leading Lotus Bakeries investment fund FF2032. Earlier experience includes Bain and finance or strategy work at Alpro.

Alamar Biosciences, Inc. is a Fremont, California precision-proteomics technology company incorporated in Delaware in May 2018 and publicly traded on Nasdaq as ALMR following its April 2026 IPO. Its NULISA protein-detection assays and ARGO automated instruments measure very low-abundance proteins in small biological samples for biomedical research. The platform combines immunoassay engineering, molecular amplification and high-throughput readout, with analytical tools and an executive function for AI and strategic initiatives. Its neurological research products include CNS Disease and Neuro panels and assays for Alzheimer-associated brain-derived phosphorylated tau, neurofilament light and other protein biomarkers. These tools support neuroscience research and biomarker discovery; the published commercial products are for research use only and not for diagnostic procedures. An ARGO DX clinical-development programme and related planned regulatory submissions are distinct from current clearance. Research collaborations with the Alzheimer’s Disease Data Initiative and Gates Ventures do not by themselves establish equity investments. The Alzheimer’s Drug Discovery Foundation programme is a milestone-based research-funding commitment of up to USD10 million over 36 months, rather than USD10 million of cash paid upfront. Confirmed issuer fundraising includes the 2021 Series B, February 2024 Series C, January 2026 convertible notes and completed April 2026 IPO; prior preferred-share and note conversions at the IPO are not additional cash. Alamar founded Attovia Therapeutics and contributed platform intellectual property in exchange for equity, but distributed its remaining Attovia interest to shareholders in February 2024 and retained no Attovia shares following that transaction. Its current leadership includes co-founders Yuling Luo and Shiping Steve Chen, president Tod White, CFO Justin McAnear, CTO Xiao-Jun Ma, CSO Stephen Williams and a board that now includes former GRAIL CEO Bob Ragusa. Alamar is distinct from unrelated Alamar-branded entities and from its former therapeutic spinout.

Vincent De Smet is listed by Korys as Senior Investment Manager. He supports the Conscious Consumer investment strategy. His academic background includes organizational psychology and postgraduate finance studies.

A biochemist and entrepreneur who co-founded Alamar Biosciences after leading Advanced Cell Diagnostics until its acquisition by Bio-Techne. He invented RNAscope, previously co-founded Panomics and Avida Biomed, and co-founded Attovia Therapeutics. He is also an Illumina Ventures venture partner. He holds a chemistry degree from USTC and a biochemistry doctorate from Case Western Reserve University. IlluminaVentures currentownpublished affiliation: Venture Partner. Yuling is a technologist and serial entrepreneur and has spent his entire career in life sciences startup companies. He is currently the founder, chairman and CEO of Alamar Biosciences, a startup company developing game-changing technologies for early detection of cancer and other diseases. Yulong is the inventor of RNAscope, a breakthrough molecular detection technology that has become increasingly popular for life sciences research and diagnostics. As the founder, president and CEO of Advanced Cell Diagnostics (ACD), he led the company from concept to successful product launch and commercialization. Under his leadership, ACD has become one of the fastest growing life sciences company, which was acquired by Bio-Techne for $325M in 2016. Yuling and his team have created $300M value for ACD shareholders. Before ACD, Yuling was a co-founder of Panomics (previously named Genospectra before its acquisition of Panomics), a life sciences company that was acquired by Affymetrix in 2008. At Panomics, he served in various roles including vice president, Functional Genomics and chief scientific officer, and he led the development and launch of all its flagship products. Prior to Panomics, Yulong was one of the earliest senior scientists at Exelixis, now a NASDAQ company, where he led a team to identify and validate novel therapeutic targets. Yuling has published numerous research papers in top peer-reviewed journals and his inventions are the subject of more than 30 issued patents. Yuling received a Bachelor of Science in Chemistry from the University of Science & Technology of China and earned a PhD in Biochemistry from Case Western Reserve University in Ohio. Portfolio involvement is institutionalboard/support context, not personalcash attribution.

Hilde Van der Straeten is listed by Korys as Investment Director. She invests in the Conscious Consumer strategy with an emphasis on health and environmental impact. She joined in March2022 after thirteen years at PMV and earlier work at Belfius and Mitiska.

Swati Lakhotiya is listed by Korys as Investment Analyst. She evaluates investment opportunities after research at VisibleAlpha, ratings work at Moody’s and impact investing at Caspian, including climate and deep-technology exposures.

Srinivas Vobilisetti is listed by Korys as Investment Manager. He supports Indian portfolio businesses and fund relationships, helping develop partnerships with entrepreneurs and other investment managers.

Hari Subramanian is listed by Korys as Partner India. He develops the India portfolio and represents the platform on investment committees and boards. His background spans technology, retail, banking and renewable energy; he also leads Colruyt Group India.

Griet Aerts is listed by Korys as Advisor. She advises Korys while developing the Cozin Family Office. She joined in 2021, served as partner until 2026 and previously worked at Colruyt Group, the World Economic Forum and Procter & Gamble.

Vincent Vliebergh is listed by Korys as Advisor. He advises the board and management after serving as managing partner from the platform’s formal establishment in2012 until2022. Earlier experience includes Solvay, ArthurD.Little, Putnam and GoldmanSachs.

Stefaan Vandamme is listed by Korys as Partner. He leads liquid investing, corporate operations and shareholder relations. He joined in mid-2026 after senior finance and operating positions at Colruyt Group and Van de Velde.

Dries Crevits is listed by Korys as Partner. He oversees direct and fund investing after seven years at PMV and earlier financial-sector positions. His education combines law and economic law.

Korys is the Colruyt family’s evergreen investment platform, formally established in2012, with teams in Belgium, Luxembourg and India. Its official website identifies Korys Investments NV, Belgian enterprise BE0844.198.918, as the operating data-controller company. This public platform is distinguished from Korys NV and other family holding or business-services entities; their exact legal subscriber capacities are not assigned to every portfolio investment. It invests directly and through funds across energy transition, conscious consumption and life sciences, and also manages liquid listed-equity and multi-asset investments. Relevant exposures include AI energy trading, grid monitoring, retinal surgical robotics, genomic tools and investigational neurodegenerative-disease drug development. The current official directory names36people in investment, advisory, India, liquid-market and corporate-support capacities. Korys supplies patient family capital; family wealth, assets under management and portfolio-company financing totals are not LP fund closes. Its sustainable multi-asset fund is publicly confirmed but its legal vehicle name, closed capital and closing day are not published. Korys sponsors and advises the separate OMX Europe Venture Fund FPCI, which is managed by Mérieux Equity Partners; the historical EUR90M target and unspecified initial subscriptions are not treated as a Korys fund close or direct ownership of every OMX investee.

Benjamin Reydellet is a directeur général of Relyens Innovation Santé, named in the official July 2025 French BODACC administration notice. Relyens’s own 2023 activity report identifies him as finance director and publishes his named original portrait. The earlier parent title is source-qualified and does not establish his current parent-company title.

Claire Poulard is an investment director at Turenne Santé, the healthcare division advising Relyens Innovation Santé. DeepLife’s original December 2024 financing release quotes her for the Relyens Innovation Santé investment; the current adviser team directory publishes her title and authentic portrait. Her adviser affiliation is qualified rather than treating her as an employee of the corporate investment vehicle or a personal investor.

Edwige Rossignol is a directeur général of Relyens Innovation Santé, named in the official July 2025 French BODACC administration notice. Relyens’s own public reporting identifies her as Group Chief Financial Officer; an earlier native professional portrait identifies her in the healthcare-market leadership team. Parent-company duties are distinct from this subsidiary’s executive mandate.

Sandrine Pernette is Relyens’s investment director, identified on the dedicated Relyens Innovation Santé page as the investment leader presenting its healthcare venture strategy. The corporate vehicle invests in medical devices, digital health and biotechnology and is advised by Turenne Santé. This oversight affiliation does not establish a personal investment.

Relyens Innovation Santé (formerly SHAM Innovation Santé) is the dedicated healthcare corporate venture investment vehicle of the European mutual insurance group Relyens. The active French SAS, SIREN 801985995, operates as a société de capital risque (SCR) and is advised by Turenne Santé, the healthcare division of Turenne Groupe, since its 2014 launch. The corporate investing vehicle is distinct from its insurer parent and its external adviser; a named Relyens investment does not create a second Turenne cash investment. It backs disruptive biotechnology, medical devices, diagnostics and digital-health technologies addressing substantial unmet needs, including neuroscience and AI-enabled drug discovery. Its own public portfolio names DeepLife, Carthera, BrainEver and Coave among 17 current companies. Its stated initial equity range is EUR 0.5–3M, with cumulative investment up to EUR 7M per company; these ranges are not actual disclosed tickets. The own page reports over EUR 60M invested and 10 exits, which are cumulative activity metrics rather than a closed LP fund. Its public branding is the shared Relyens mark, verified on the dedicated vehicle page and on a vehicle-specific Kimialys financing release. Sandrine Pernette provides Relyens investment oversight, while Edwige Rossignol and Benjamin Reydellet are the latest official named directeurs généraux; Claire Poulard’s role is qualified as an external Turenne adviser. Parent insurance staff and all unrelated Turenne division staff are not imported as vehicle employees.

Jakob E. Larsen joined DeepLife’s Advisory Board in September2026. The issuer says he spent fifteenyears at NovoNordisk leading target-discovery efforts and brings global pharmaceuticalR&D and strategic experience, advancing earlydiscovery through innovative science and digital approaches. His advisorywork supportsDeepLife TwinCell causal-cellmodels, targetidentification and indicationexpansion. The nativeannouncement explicitly says formerNovoNordisklead; it does not assertcurrentemploymentthere, exactservice dates or personalinvestment.

Ivan Griffin joined DeepLife’s Advisory Board in September2026. He co-founded BenevolentAI and brings nearlytwenty years of life-sciences, technology, investing and company-building experience. BenevolentAI’s own2022 annualreport identifies his prior investing at IPGroup and Nesta, work helpinglaunchGenomicsEngland in2013, and an Oxford DPhil in CognitiveNeuroscience with postdoctoralresearch. Those historical affiliations do not assert unchangedcurrentBenevolentoperatingrole or a personalDeepLifeinvestment.

Pascal Borderies is Head of US Partnerships at DeepLife, as explicitly published on the company’s June2025 BIO conference team directory. This is a dated last-confirmed affiliation; continuedOctober2026 service is not independently established. The company develops AI digital twins of cells and drug-discovery tools; no personal cash investment is inferred.

Constance Beyer is Head of Business Development, EMEA at DeepLife, as explicitly published on the company’s June2025 BIO conference team directory. This is a dated last-confirmed affiliation; continuedOctober2026 service is not independently established. The company develops AI digital twins of cells and drug-discovery tools; no personal cash investment is inferred.

Jean-Baptiste Morlot co-founded DeepLife in2019 and serves asCTO. His ownSorbonneUniversity interview identifies him as a2018PhD graduate whose work applied physics tools tomodel biologicalsystems. He met hiscofounder throughEntrepreneurFirst, whichprovided initiallaunchcapital, anddescribes laterfundraising completedOctober2020. He coordinates scientific/technical productdevelopment ofAIcell-modeling tools; currentCEOCTOidentitycorroborated nativeAbout andFeb2026event.

Claus joined Novo Holdings A/S in November 2019 as Finance Director, responsible for accounting, reporting, controlling and tax, as well as facility management. Today, Claus is Executive Director, Head of Finance responsible for accounting, valuation, tax, investment operations and financial planning & analysis as well as facility management. Prior to joining Novo Holdings, Claus has taken up various positions in Novo Nordisk, amongst others Finance Director for Region AAMEO based out of Dubai, CFO for Business Area CIS based out of Moscow and Business Support Director of Global Service Center in Bangalore. Other previous employments include Budget and Planning Manager at Coca Cola Tapperierne A/S and Auditor at PWC. Claus holds a Master Degree in Auditing at Copenhagen Business School.

Colby Ye joined Novo Holdings in 2022 and is based in the Boston office. He participates in deal sourcing, execution, and portfolio management across the healthcare sector. Colby has been involved in principal investing since 2016. Prior to Novo Holdings, he was a Vice President at Milestone Capital, where he worked on public and private equity investments. Prior to Milestone, he was an Associate on the private equity team at Berkshire Partners. Colby began his career in the AIMS Private Equity Group at Goldman Sachs. He holds a BA in Economics and Engineering Sciences from Dartmouth College and an MBA from Harvard Business School.

Cynthia Kueppers joined Novo Holdings in June 2024 as a Partner on the Planetary Health Investment team. Previously, Cynthia was a Managing Director at Riverstone Holdings, where she invested in the industrial decarbonization growth equity strategy. Prior to her investing career, she was an investment banker at Merrill Lynch and then Barclays Capital where she focused the transportation and infrastructure sectors. Cynthia serves as a board member for various portfolio companies, and serves as Treasurer at UnionDocs, a center for the documentary arts. She has an MBA from the Yale School of Management, a BA from the University of Pennsylvania, and is a Chartered Financial Analyst (CFA).

Danielle joined Venture Investments (US) Inc. in San Francisco, California in 2017 as Venture Coordinator. She assists with the administration and support for the San Francisco office of Venture Investments (US) Inc. Danielle received a Bachelor of Arts degree from San Francisco State University. Before joining Venture Investments (US) Inc., she worked for a capital management firm, providing project and administrative support to the CEO and other members of the firm’s executive management team.

Liz Allen is Senior Marketing & Communications Manager at DeepLife, as explicitly published on the company’s February19,2026 Infinite event team directory. The company develops AI digital twins of cells and drug-discovery tools; no personal cash investment is inferred.

Martina Lubrano di Ricco is Chief of Staff at DeepLife, as explicitly published on the company’s February19,2026 Infinite event team directory. The company develops AI digital twins of cells and drug-discovery tools; no personal cash investment is inferred.

Christoffer Smed Karlog is listed by Novo Holdings as Manager in Finance & Operations. Further biography is not published on the reviewed profile.

Christopher Shen joined Novo Holdings in 2024 as a Partner on the Ventures team and is based in San Francisco. He brings 20+ years of global healthcare investment experience. Prior to Novo, Chris was a Managing Director at CBC Group, where he focused on US/Europe/Asia medical technology investments. Previously, he co-founded the US healthcare venture investing arms at Temasek/Vertex Healthcare and Qiming Venture Partners. He began his investment career at New Enterprise Associates. Chris initially transitioned from clinical medicine to industry working as a Senior Design Engineer at Guidant Corporation, where he was the principal inventor on one of the earliest stentriever devices for ischemic stroke. Chris is also an Adjunct Professor of Medicine at Stanford University, responsible for training and mentoring international and Stanford-based faculty and students in medical technology innovation. Chris received his MD, MBA, and MS Biomechanical Engineering from Stanford University.

Christoffer joined Novo Holdings A/S in December 2018 in Principal Investments. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings A/S, Christoffer worked as an Analyst at Danske Bank Corporate Finance in their Copenhagen office. During this time, Christoffer worked with both private and public transactions across a broad range of sectors. Christoffer holds a BSc in International Business and an MSc in Finance and Accounting from Copenhagen Business School.

Christoffer joined Novo Holdings A/S in February 2016 as Director, Principal Investments. Today, Christoffer is Managing Partner and Head of Principal Investments. Prior to joining Novo Holdings A/S, Christoffer was Senior Principal at BCG leading the Copenhagen Private Equity and Principal Investors practice area. Prior to joining BCG, Christoffer worked at Falck A/S as Global Head of Group Strategy and M&A, and most recently as CFO Falck Assistance. Prior to joining Falck, Christoffer worked as Director at Carnegie Investment Banking focusing on buy-and sell-side M&A. Christoffer holds a BSc in International Business and an MSc in Finance and Accounting from Copenhagen Business School.

Yann Abraham is Head of Drug Discovery at DeepLife, as explicitly published on the company’s February19,2026 Infinite event team directory. The company develops AI digital twins of cells and drug-discovery tools; no personal cash investment is inferred.

Christian joined Novo Holdings in September 2026 as a Senior Associate in Capital Investments. As part of the Real Assets team, he participates in deal sourcing, execution, and portfolio management of real estate and infrastructure investments. Prior to joining Novo Holdings, Christian worked in the Corporate Finance department at Danske Bank, covering both M&A and equity capital markets advisory.        Christian holds a MSc in Finance and Accounting and a BSc in European Business, both from Copenhagen Business School.

Christian joined Novo Holdings A/S in October 2014 as Asset Director, Principal Investments, taking part in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings, Christian was employed as a Principal in A.T. Kearney’s global health practice, working with strategy, M&A, and commercial & operational excellence across the MedTech & Pharmaceutical industries. Other previous employments include a position as Senior Vice President, Emerging Markets with Coloplast A/S. Christian holds a MSc in Manufacturing from the Technical University of Denmark.

Christiana joined Novo Holdings A/S in August 2022 as an Associate in Principal Investments. She participates in deal sourcing and execution as well as in managing the growing portfolio of investments. Prior to joining Novo Holdings A/S, Christiana worked in Investment Banking at Goldman Sachs, focusing on both private and public transactions across a broad range of sectors. Christiana holds a BSc in Economics from Insper Instituto de Ensino e Pesquisa and a MSc in Advanced Economics and Finance from Copenhagen Business School.

Christine joined Novo Holdings in February 2017 as Assistant in Venture Investments and she provides the team with administrative support. Before joining Novo Holdings, Christine worked as Recruitment Assistant at SimCorp. Prior to this she worked 5 years as Executive Assistant at Spencer Stuart International providing project and administrative support to the team in Copenhagen. Christine holds a MSc degree from Copenhagen Business School.

Elie Hatem is Head of Assets Development & Strategic Programs at DeepLife, as explicitly published on the company’s February19,2026 Infinite event team directory. The company develops AI digital twins of cells and drug-discovery tools; no personal cash investment is inferred.

Jonathan Baptista co-founded DeepLife in2019 and serves asCEO. A systemsengineer and former aeronautics simulationtool specialist, he combined that background with Jean-BaptisteMorlot’s AI/genetics expertise tobuild digitaltwins ofhumancells. He leads the AI drugdiscovery/therapeuticrepositioning business. The company’s native2026event explicitlyconfirms hisrole and authenticnamedportrait.

DeepLife SAS is a French AI drug-discovery company founded in 2019 by Jonathan Baptista and Jean-Baptiste Morlot. Based in the Paris healthcare ecosystem with an international, remote-first team, it develops digital twins of human cells to identify therapeutic targets, model disease mechanisms and evaluate drug-repositioning opportunities. Its TwinCell causal models and Cell Blueprint platform combine single-cell multi-omics, systems biology and artificial intelligence to study interventions that could restore diseased cells toward healthier states. The company publishes exploratory research interests in autoimmune disease, Alzheimer’s, Parkinson’s, multiple sclerosis and glioblastoma. These discovery programs are distinct from approved treatments. Its scientific and industry collaborations include healthcare and biotechnology partners. DeepLife completed a USD 10 million Series A in December 2024, co-led by YZR Capital and Relyens Innovation Santé, with the latter advised by Turenne Capital. Beiersdorf Venture Capital, Groupe Prunay and historical investors participated. A primary October 2022 announcement reports an earlier EUR 6 million financing package involving institutional investors and individual angels; the instrument mix and individual allocations are undisclosed. Earlier launch and October 2020 financing amounts are also undisclosed. DeepLife is registered in France under number 852661230.

Chanie joined Venture Investments (US) Inc. as an Associate in the Boston location in August 2022. Chanie previously worked in corporate strategy and business development at Evozyne Biosciences, an early stage AI/ML generative biology company. Prior to Evozyne, she was a Senior Associate on Evercore ISI’s Biotech Team where she focused on coverage of SMID-cap biotechnology companies. Chanie holds a PhD in Immunology from the University of Chicago, where she studied the role of the immune system in respiratory disease. She also holds a BSc/MSc dual degree with a concentration in Immunology from Emory University.

Charles joined Novo Holdings Equity US in June 2021. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in the United States. Prior to joining Novo Holdings Equity US, Charles was a Vice President at Anchorage Capital Group where he made equity and credit investments across public and private markets. Prior to Anchorage, Charles was on the healthcare private equity team at CVC Capital Partners. He holds a BSc in Economics from the Wharton School of the University of Pennsylvania.

Board positions Chairman of the Board, Envu Member of the Board, Teva Pharmaceuticals Career highlights 2020–2023: Chief Financial Officer, Syngenta Group 2014–2020: President & CEO, ADAMA 2013–2014: President & CEO, China National Agrochemical Corporation (CNAC) 2006–2013: Deputy CEO & Head of Global Operations, ADAMA 1999–2006: Executive Director, Investment Banking, Goldman Sachs Education Chen holds a PhD in Business Administration from the Stanford Graduate School of Business and a JSD from Stanford Law School. He also earned a BSc in Physics and an LLB from the Hebrew University of Jerusalem.

Christel joined Novo Holdings A/S as Personal Assistant in 2019. Prior to joining Novo Holding, Christel was employed as PA / Project Coordinator in the executive search company Odgers Berndtson for more than 10 years. Other previous employments include positions with Brunata, VELUX and IBM. Christel holds a Master’s degree in International Business Communication from CBS .

Formerly Corporate Officer, Takeda Executive Team, leading global portfolio commercialisation and global commercial excellence Board Director at F2G (UK/US) and Affibody AB (Sweden) Industrial Advisory, private equity group EQT Earlier served in various senior operational and strategic roles at Shire, Roche, Abbott (now AbbVie), Schering Plough (now Merck & Co.) and McKinsey & Co. in Europe, US and Asia

Campbell joined Venture Investments in 2022 as a Senior Associate. Previous to that, Campbell was an Associate in the Healthcare Team at Rothschild and Co investment bank in London with a primary focus on Biotech transactions. Campbell has worked on a broad range of Biotech transactions including sell-side and buy-side M&A deals, licensing deals, royalty financings and strategic reviews. Campbell holds a degree in Clinical Medicine (BMBCh) and a Masters degree in Medical Sciences with a focus on cardiovascular physiology, both from the University of Oxford.

Carol joined Novo Holdings Asia in 2021 as Senior Associate. She participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments, focusing primarily on the markets in China, India, and Southeast Asia. Prior to joining Novo Holdings Asia, Carol was Senior Investment Manager at Fosun International in Shanghai for more than 4 years. During this time, she worked on both private and public healthcare investment opportunities across the Asia-Pacific region. Before this, Carol worked as  Equity Research Associate at UBS covering Greater China healthcare sector listed in HK and US, and Portfolio Manager Assistant at Raymond James in Toronto. Carol holds an MBA with major in Finance from McMaster University in Canada.

Celine Nguyen Trung is listed by Novo Holdings as HRIS & Data Manager in Strategy and People. Further biography is not published on the reviewed profile.

Bo joined Novo Holdings in March 2025 as a Senior Procurement Specialist in Finance & Operations. In this role, he is responsible for the Global Novo Holdings Procurement function, including driving effective Procurement and Contract Management processes. Prior to joining Novo Holdings, Bo worked as Head of Contract Management at PFA where he has built up effective contract and supplier management. Before his tenure at PFA, Bo worked as a Strategic Analyst at Tryg.   Bo holds a BSc in Economics and Business Administration and a MSc in Supply Chain Management from Copenhagen Business School.

Member of the Novo Holdings Board since 2022. Vice Chair of the Board since 2025. Britt Meelby Jensen was born in 1973 and is a Danish national. She received a MSc in International Marketing and Management from Copenhagen Business School in Denmark and furthermore received an MBA from Solvay Business School (Université Libre de Bruxelles) in Brussels. Between 2000-2002, Britt Meelby Jensen worked as a Management Consultant in McKinsey & Company before she joined Novo Nordisk A/S in 2002, where she held several global commercial leadership roles. Hereafter she has held CEO roles at Dako A/S, Zealand Pharma A/S, and at the Swedish MedTech company, Atos Medical AB. In 2022, Britt Meelby Jensen was appointed as CEO of Ambu A/S where she had served as Board member since 2019. Other Board Positions and Management Duties: CEO, Ambu A/S, Denmark Board Member, Novo Nordisk A/S, Denmark Board member of the Industry Association for Employers in Denmark, IAD, and the Confederation of Danish Industry, DI

Buster joined Novo Holdings in May 2023 as an Associate in Capital Investments. As part of the Real Assets team, he participates in deal sourcing, execution, and portfolio management of real estate and infrastructure investments. Prior to joining Novo Holdings, Buster worked in the Corporate Finance department at PwC as an M&A advisor and at AIP Management, a Copenhagen based infrastructure fund. Buster holds a MSc in Finance and Strategic Management and a BSc in International Business from Copenhagen Business School.

Camilla Hansen joined the Novo Holdings Seed Investments team in June 2018. She leads the REPAIR Impact Fund and drives company creation and maturation under Novo Holdings’ Seed Investments strategy. Before joining Novo Holdings, Camilla spent 10 years in business development across academic start-ups, emerging biotechs, and industry. Camilla serves on the boards of Muna therapeutics, Centauri Therapeutics, and the AMR Action Fund. She previously served on the board of Limmatech Biologics, which was acquired by Lilly in 2026. Camilla holds a PhD in Medicinal Chemistry and a Master of Pharmacy from the University of Copenhagen.

Benjamin joined Novo Holdings A/S in August 2025 as a Principal in Capital Investments, to source and execute private equity investments. Prior to joining Novo Holdings, Benjamin spent 10 years at Ardian in London focusing on European buyouts as a majority and active shareholder. Prior to this he was with the Leveraged Finance & Sponsors team at Credit Suisse. Benjamin holds an MSc in Engineering from Imperial College London and an MSc Grande Ecole from ESCP in Paris.

Betina joined Novo Holdings A/S in 2021. She is part of the Novo Holdings A/S’ tax team handling all tax matters within the company and the fund, including in particular support to deal investment teams on mergers & acquisitions, tax compliance & reporting for assets under management and support of the responsible tax agenda of the company. Prior to joining Novo Holdings A/S, Betina was employed at PwC Denmark for 4 years, where she advised Clients on tax aspects of M&A transactions, structuring, tax compliance and other domestic as well as international corporate tax issues. Before that, Betina was employed with KPMG Denmark (merged into EY Denmark in 2014) for more than 6 years also within a deals tax department and a short period as a Tax Manager in European Energy in 2017. Betina holds a Msc in Business Administration and Commercial Law (Cand.Merc.Jur.) from Copenhagen Business School (2011).

Bettina joined Novo Holdings in February 2024 as a Senior Investment Operations Specialist in Finance & Operations. Prior to joining Novo Holdings, Bettina worked 25 years in the financial sector. First 16 years in FIH Erhvervsbank as a senior controller, then 2 years at Nykredit and latest 7 years at Alm. Brand Group as system administrator for Simcorp Dimension. Bettina holds a Master Degree in Finance and Accounting.

Bianca Mortensen is listed by Novo Holdings as Sustainabilty & Impact Specialist in Finance & Operations. Further biography is not published on the reviewed profile.

Asger joined Novo Holdings in October 2026 as a Senior Strategy Consultant in the Strategy Office. Prior to joining Novo Holdings, Asger was employed at EY-Parthenon working with corporate strategy and commercial due diligence projects. Asger holds a MSc in Applied Economics and Finance and a BSc in International Business and Politics from Copenhagen Business School.

Aske joined Novo Holdings in August 2023 as a Senior Business Intelligence Specialist in Digital & BI. As part of the Digital & BI team, Aske is the lead Power BI developer and develops the PBI reporting solutions for Novo Holdings. Additionally, Aske actively contributes to the enhancement of cloud-based solutions and automation initiatives within the BI team. Before his tenure at Novo Holdings, Aske garnered experience through engagements at Saxo Bank as a Business Intelligence Analyst, and during an interlude at Next Agenda, a specialized BI consulting firm. He holds a BSc. in International Business & Politics from CBS and a MSc in Financial Technology from University of Strathclyde.

Barbara joined Novo Holdings A/S in 2020 as General Counsel and has since 2021 been part of the Executive Leadership Team. In her role, she is heading the legal department and overall responsible for handling all legal affairs of the company, including providing legal advice and assistance to all investment teams whether on new investments, divestments/exits or matters relating to portfolio companies. Prior to joining Novo Holdings A/S, Barbara worked for ISS World Services A/S, where she was responsible for the legal aspects of the activities in the Europe region and for legal compliance and corporate governance group-wide. In addition, Barbara was part of the transaction teams on multiple M&A transactions across the world. Before that, Barbara worked as senior legal counsel for Genmab A/S, dealing with the company’s large partnerships, in- and out-licensing and collaboration agreements. From 2011 to 2013 she worked for Genmab US, Inc. in New Jersey, US. During her earlier career she was employed as attorney-at-law at the law firm Plesner in Copenhagen, specialising in M&A. Barbara holds a Master in Law from the University of Copenhagen (1999) and is a member of the Danish Bar Association.

Anette joined Novo Holdings A/S in February 2025 as Tax Manager. Prior to joining Novo Holdings A/S, Anette worked as Tax Manager at Chr. Hansen (now part of Novonesis). During her years as an in-house Tax Advisor, she contributed to M&A transactions and their implementation, ensured tax compliance, and led tax governance initiatives. Her career began as a tax advisor at Deloitte, followed by in-house tax roles at LEGO System A/S, and Siemens Gamesa Renewable Energy A/S, before joining Chr. Hansen in 2019.

Angela Jong joined Novo Holdings in 2025 as a Principal in the Planetary Health Investments team. Prior to joining Novo Holdings, Angela was a Vice President at Advent International focusing on buyout investments in healthcare. She also previously worked at Stellar Health, a healthcare technology startup, and at TA Associates, focusing on growth and buyout investments in healthcare. Angela began her career in the Investment Banking division of Morgan Stanley.

Angie joined Novo Holdings in 2026 as an Associate in the Principal Investments group. Prior to joining Novo Holdings, Angie was an investment banking analyst in the Healthcare group at Lazard. Angie holds a B.S. in Neuroscience from Duke University.

Anna is a Senior Partner and leads the public investing strategy for the Venture Investments team. She also serves on the Novo Holdings Life Sciences Operating Committee. Anna is based in San Francisco, California. Prior to joining Novo Holdings, Anna was responsible for covering publicly traded biotech companies at Sectoral Asset Management. She began her career in financial advisory working with fund managers and corporate clients in the life sciences industry. Anna earned her Ph.D. and B.Sc. in Biochemistry, both from McGill University. She is a CFA charterholder.

Anne Dorte Stensberg Jensen joined Novo Holdings A/S as Executive Assistant in Principal Investments in April 2024. Prior to joining Novo Holdings A/S, Anne Dorte was employed as PA at Copenhagen Infrastructure Partners. Other previous employments include PA and Customer Service Assistant at WS Audiology A/S. Anne Dorte holds a BA degree in German Business Communication from the University of Southern Denmark.

Annette Borring Kjær joined Novo Holdings A/S as Executive Assistant in Planetary Health Investments in April 2025. Prior to joining Novo Holdings A/S, Annette was employed as Executive Assistant to the CEO and Manager of the PA team in Zealand Pharma. Annette has more than 20 years of experience as an EA and team leader, primarily in the life sciences sector. Throughout her career, she has supported senior executives and boards. Annette holds a Hotel Management diploma from Schloss Klessheim in Salzburg, Austria, and is fluent in English and German

Andreas joined Novo Holdings in March 2022 as Partner within Novo Capital Investors. Andreas holds a MSc in Economics from University of Copenhagen and is a CFA Charterholder from 2011. Prior to joining Novo Holdings Andreas was employed at Realdania, Sampension and Ørsted.

Anette Brammer is listed by Novo Holdings as Head of Workspace and Facility Management in Finance & Operations. Further biography is not published on the reviewed profile.

Amy Kacprowicz joined Novo Ventures (US), Inc. as an Office Manager in the Boston location. In 2023, she joined the People & Organization team as an HR coordinator, supporting HR operations in the Boston and San Francisco offices. Amy holds a Bachelor of Arts degree from Hobart and William Smith colleges. In 2020, Amy received a graduate certificate in Human Resources from Northeastern University. Prior to joining Novo Ventures (US), Inc., she held various positions in healthcare administration, providing project and administrative support.

Anders joined Novo Holdings A/S in 2017. Anders is Managing Partner and Head of the Planetary Health Investments team. Prior to joining Novo Holdings, Anders was employed as VP in Xellia Pharmaceuticals heading up the Global Product Supply. Other previous employments include EVP, Global Product Supply at Leo Pharma A/S and VP Global Supply Chain at Novozymes A/S. Anders holds a PhD in Biotechnology and a MSc in Chemical Engineering from Technical University of Denmark as well as a graduate diploma in Business Administration (International Business) from Copenhagen Business School.

Anders joined Novo Holdings A/S in November 2017 as an Associate in Principal Investments. He participates in deal sourcing and execution, as well as in managing the existing portfolio. Prior to joining Novo Holdings A/S, Anders worked as a management consultant at Bain & Company in Copenhagen. During his time at Bain, he worked mainly with PE clients on due diligence and post-acquisition projects, as well as with large Nordic corporates on strategy, performance improvement and M&A. Anders holds a BSc in International Business and MSc in Finance & Strategic Management from Copenhagen Business School.

Andeta joined Novo Holdings in 2021 as compliance specialist and will split her time 50/50 between the Finance team and the Ventures team. Prior to joining Novo Holdings, Andeta worked 12 years in the banking sector. She was in charge of financial closing controls, multiple compliance tasks including Know Your Client as well as activities and reporting of various statements. Andeta holds a Master Degree in Financial Management.

Álvaro joined People & Organisation in 2024 as a Rewards Manager. In his role, he works on initiatives related to the governance of our reward frameworks, in line with our business principles and strategy. Before joining Novo Holdings, he was working as Manager, Performance & Rewards Partner in Pandora A/S. He has also built previous rewards experience in tech and security companies. Álvaro is a Spanish national and holds a MChem in Chemistry and Materials Chemistry from the University of Edinburgh.

Amalie joined Novo Holdings A/S in February 2025 as a Senior Associate in the Planetary Health Investments team. She participates in deal sourcing and execution as well as in managing the existing portfolio of investments. Prior to joining Novo Holdings, Amalie worked in Investment Banking at ABG Sundal Collier, focusing on M&A and ECM transactions across various sectors. Amalie holds an MSc in Finance and a BSc in Economics and Business Administration from Aarhus University BSS.

Amer Sheikh joined Novo Holdings Seed Investments in January 2026 as a Partner, where he leads Novo Holdings’ dedicated Quantum Technologies investment strategy. His focus includes quantum computing and sensing, advanced computing, and enabling software and infrastructure, with an emphasis on technologies that have the potential to deliver long-term scientific, industrial and societal impact. Amer brings over a decade of global investment experience across venture capital, growth equity and corporate venture investing, spanning Europe, North America, the Middle East and Asia. Prior to joining Novo Holdings, he was an Investment Director at HSBC Ventures, with responsibility for leading the firm’s Quantum and Deep Tech investment themes across quantum technologies, advanced computing, artificial intelligence and cybersecurity. He previously held senior investment roles at Sky Ventures and Centrica Ventures, where he played a key role in building and managing international portfolios across enterprise software, deep technology, climate and sustainability. Amer has served as a board director and observer for several high-growth technology companies, supporting management teams on strategy, scaling and governance. He holds a PhD in Physics from Loughborough University and the Institut Laue Langevin and a BSc (Hons) in Physics.

Amit joined Novo Holdings Asia in August 2020 as Head of Asia to lead investments and partnerships across the region, focusing primarily on the markets in China, Japan, Singapore and Southeast Asia. Amit has more than 25 years of healthcare experience with several senior management roles across the globe and having worked in India, China, Singapore and the USA. Previously, he has been with Everlife Asia based in Singapore as Head of M&A and Business Development, with the Avenue Capital Group as Head of healthcare investments for Asia and with GE Healthcare in several senior leadership positions. Amit is a Medical Doctor with a postgraduate degree in Radiation and Nuclear Medicine from Tata Memorial Hospital and Cancer Centre in Mumbai, India.

Bonnie Miao Bandeen is Board of Directors member at the Michael J. Fox Foundation for Parkinson’s Research. The foundation’s own board directory and individual biography confirm this governance affiliation. This is not an assertion of operating employment or personal investment.

Holly S. Andersen is Board of Directors member at the Michael J. Fox Foundation for Parkinson’s Research. The foundation’s own board directory and individual biography confirm this governance affiliation. This is not an assertion of operating employment or personal investment.

Skip Irving is Vice Chairman, Board of Directors at the Michael J. Fox Foundation for Parkinson’s Research. The foundation’s own board directory and individual biography confirm this governance affiliation. This is not an assertion of operating employment or personal investment.

Abhijeet joined Novo Holdings A/S in September 2020 as Senior Partner and Head of US Principal Investments. He brings 20+ years of healthcare investment experience.  Prior to Novo, Abhijeet led US healthcare investing for Temasek which he joined from Investor AB/Patricia Industries, where he headed US healthcare investing. Abhijeet started his investing career at EGS Partners, a healthcare focused hedge fund.  Before investing, Abhijeet was Engagement Manager at McKinsey & Company and held operating positions in the pharmaceutical industry. Abhijeet holds an MA in Natural Sciences from Cambridge University and an MBA from Cornell University.

Alan joined Novo Holdings A/S in 2020. He participates in deal sourcing and execution as well as in managing and developing the growing portfolio of investments. Prior to joining Novo Holdings, Alan worked in J.P. Morgan’s European Healthcare team in London and North Asia M&A team in Hong Kong. During this time, he worked on both private and public transactions across a broad range of industries. Alan holds a BSc in Quantitative Finance from CUHK, an MPhil in Biotechnology from Cambridge and an MSc in Integrated Immunology from Oxford.

Aleks joined Novo Holdings in 2014 and is Partner in the Planetary Health Investments team and is based in Boston.  He was previously part of the Principal Investments team and the Seed Investments team based in Copenhagen. Prior to joining Novo Holdings, Aleks was employed by Baxter International, Pfizer Global Research and Development, Thomson Scientific & Healthcare, and McKinsey & Company. Aleks holds a PhD in Biochemical Engineering and a MSc in Chemical Engineering Practice from Massachusetts Institute of Technology (MIT).

Andrew J. O'Brien is Chairman, Board of Directors at the Michael J. Fox Foundation for Parkinson’s Research. The foundation’s own board directory and individual biography confirm this governance affiliation. This is not an assertion of operating employment or personal investment.

Michael J. Fox is Founder at the Michael J. Fox Foundation for Parkinson’s Research. The foundation’s own board directory and individual biography confirm this governance affiliation. This is not an assertion of operating employment or personal investment.

Dan Feehan is Chief Policy & Government Affairs Officer at the Michael J. Fox Foundation for Parkinson’s Research. Dan Feehan joined The Michael J. Fox Foundation in August 2025 as its Chief Policy and Government Affairs Officer. In this role, he develops and implements a comprehensive strategic, nonpartisan policy and advocacy agenda that advances the Foundation’s goals to increase federal and state investment in Parkinson’s research, address environmental risk factors and advance the National Parkinson's Project. Dan is an accomplished leader in both public policy and politics, and a lifelong public servant with experience spanning military service, the

Prilenia Therapeutics is a clinical-stage biotechnology company developing treatments for Huntington’s disease, amyotrophic lateral sclerosis and other neurodegenerative disorders. Its lead candidate, pridopidine, is an orally administered sigma-1 receptor agonist designed to influence cellular pathways involved in neuronal function and survival. The company is evaluating pridopidine in the confirmatory Phase 3 PRECISE-HD and PREVAiLS trials. The medicine remains investigational and has not been approved. Prilenia also conducts earlier research into additional central nervous system indications and works with Ferrer on co-development and commercialization planning in Europe and selected international markets.

RIME Therapeutics is a Montreal biotechnology company developing an AI-assisted drug-discovery platform. Its function-first Disruptide platform uses AI-designed peptide probes to screen intracellular protein pockets in primary human cells. The approach links changes in disease-relevant cell biology to specific targets while generating binding and structure-activity data to guide subsequent drug chemistry. RIME combines human genetics, perturbation biology and machine learning to identify potential new therapeutic programs, initially including inflammation and immunology. Its published work is at the discovery-platform stage; it has not disclosed an approved medicine.

Physician and life-sciences finance executive, published as Lis Leiderman; previously CFO of Dewpoint, Atsena and Decibel.

Neurologist and clinical-development executive, published as Rick Munschauer; previously chief medical officer at Emalex, MedDay and Marathon.

Jason R. Dinges is an investment director at Morningside Technology Advisory LLC and has worked with the Morningside group since 2011. His work includes life-science investment and intellectual-property advice. CellCentric identifies his University of Iowa JD and chemistry PhD. Existing Prilenia board role is preserved.

Lisa Boudreau is Chief Development Officer at the Michael J. Fox Foundation for Parkinson’s Research. Lisa Boudreau joined The Michael J. Fox Foundation in July 2024 as its Chief Development Officer. She is an accomplished fundraising executive with a track record of building high-performing teams toward increased philanthropic revenue. She has spent her career raising critical funds to advance the mission and work of educational institutions, including more than 25 years of service at Harvard University. Most recently, Lisa served as dean for alumni affairs and development at Harvard Medical School (HMS). In that role,

Physician-scientist and biotechnology entrepreneur who co-founded Prilenia; formerly president of global R&D and chief scientific officer at Teva.

Computational biologist and AI researcher; University of Toronto professor and scientific co-founder of RIME, independently identified by Grove Biopharma as Philip M. Kim.

Vanessa Arnedo is Chief People Officer at the Michael J. Fox Foundation for Parkinson’s Research. Vanessa Arnedo serves as the Chief People Officer at the Michael J. Fox Foundation for Parkinson’s Research (MJFF), where she plays a pivotal role in shaping MJFF’s people strategy in alignment with its mission and strategic priorities. She works closely with MJFF’s executive leadership and the Board of Directors to ensure MJFF attracts, develops, and engages a talented workforce that thrives in an inclusive organizational culture to drive further impact towards the mission. Vanessa’s professional journey at MJFF includes several

Jim McNasby is General Counsel at the Michael J. Fox Foundation for Parkinson’s Research. Jim McNasby started with the Foundation on March 16, 2020. His team provides legal and compliance advice to the Foundation and its senior leadership. Before joining MJFF, Jim served as Managing Director, Global Sales (2017-2020) and General Counsel (2007-2017), for Marsh LLC, the world’s leading insurance broker and risk advisor. Prior to Marsh, Jim held various in-house legal positions at Kraft Foods (2004-2007) and Altria (1998-2004) in the US and abroad. He began private practice in New York at Davis

Holly Teichholtz is Chief Marketing Officer at the Michael J. Fox Foundation for Parkinson’s Research. Holly oversees the Foundation’s efforts to tell the story of how it is tangibly speeding progress toward a cure for Parkinson's disease. She manages a team whose job is to translate complex subject matter into compelling, accessible words and images, and to help these materials find the audiences who need them — Parkinson’s patients, families, researchers and clinical care providers. Through publications, marketing campaigns, media relations, creative assets, and virtual and face-to-face discussion, the Marketing and Communications team reports on

Mark Frasier is Chief Scientist at the Michael J. Fox Foundation for Parkinson’s Research. Mark Frasier joined the Foundation in 2006. As Chief Scientist, Mark works with a team of research professionals who stay closely linked to the Parkinson's research community in order to develop an aggressive and innovative agenda for accelerating research and drug development for Parkinson's disease. This ensures that MJFF research priorities reflect and best serve the ultimate needs of patients. Mark regularly meets with academic and industry researchers around the world to identify promising proposals to support, providing troubleshooting and

Brian Fiske is Chief Scientist at the Michael J. Fox Foundation for Parkinson’s Research. Brian joined the Foundation in 2004. As Chief Scientist, Brian works with a team of professionals who stay closely linked to the Parkinson's community in order to develop an aggressive and innovative strategic vision for accelerating research and drug development for Parkinson's disease. This ensures that MJFF priorities reflect and best serve the ultimate needs of patients. Dr. Fiske earned an undergraduate degree in biology from Texas A&M University and a PhD in Neuroscience from the University of Virginia. After

Sohini Chowdhury is Chief Program Officer at the Michael J. Fox Foundation for Parkinson’s Research. Sohini joined The Michael J. Fox Foundation in 2005. As Chief Program Officer, Sohini oversees the entire research programmatic enterprise, and works closely with the Foundation's executive leadership and Board of Directors in building the organization’s capacity as an unprecedented stakeholder in drug development — a nimble, resourceful, patient-focused problem-solver whose efforts are demonstrably accelerating progress toward treatment breakthroughs and a cure. Since 2017, Sohini served in the role of Deputy CEO and expanded her responsibilities as Head of Research,

Todd Sherer is Chief Mission Officer at the Michael J. Fox Foundation for Parkinson’s Research. Todd Sherer, PhD, is Chief Mission Officer of The Michael J. Fox Foundation for Parkinson's Research (MJFF). Formally trained as a neuroscientist, he is deeply focused on the organization's research strategy, charting a course for the coming era of Parkinson’s discovery and drug development. Todd’s role includes contributing to key research initiatives such as MJFF’s landmark clinical study, the Parkinson’s Progression Markers Initiative, collaborating with MJFF’s world-class roster of partners including ASAP (Aligning Science Across Parkinson’s) and major entities in

Deborah W. Brooks is Chief Executive Officer and Co-Founder at the Michael J. Fox Foundation for Parkinson’s Research. Deborah W. Brooks is Chief Executive Officer (CEO) and Co-Founder of The Michael J. Fox Foundation for Parkinson's Research (MJFF). Ms. Brooks launched MJFF with Michael J. Fox in 2000 and served as founding CEO until 2007. Since then, she served as Co-Founder and Executive Vice Chairman, overseeing the fundraising and marketing functions of the organization. Ms. Brooks stepped back into the role of CEO in May 2021 to lead the Foundation to an even stronger and more influential position

The Michael J. Fox Foundation for Parkinson’s Research (MJFF) is a US nonprofit research funder founded by Michael J. Fox and Deborah W. Brooks in2000, dedicated to accelerating better treatments and a cure for Parkinson’s disease. Its public2024 IRS Form990 identifies the exact nonprofit legal entity and EIN13-4141945. MJFF supports translational neuroscience, biomarkers, disease biology, therapeutic development and research infrastructure, including the Parkinson’s Progression Markers Initiative. The current executive directory identifies Deborah W. Brooks as CEO/cofounder, Todd Sherer as Chief Mission Officer, Sohini Chowdhury as Chief Program Officer and Brian Fiske/Mark Frasier as Chief Scientists. The homepage reports3BUSD research funded since inception; this is a cumulative philanthropic research statistic, not a pooled LP fund close or a new company cash investment. Research grants and programme awards remain distinct from equity investments; a published award amount does not independently prove timing of paid cash. Board, founder/patient councils and the large Fox Advisors network are governance/volunteer/advisory affiliations rather than all operating employees.

Hallstone Ventures is a Los Angeles-based seed investment manager backing software and AI infrastructure for media, entertainment and advertising. It invests in tools that help creative businesses operate and monetize, advertising measurement and decision systems, immersive and spatial production technologies, and emerging media infrastructure. The firm supports founders through sector expertise, introductions to buyers and an operator network spanning studios, streaming services and technology companies. Founder Seth Hallen and four venture partners bring experience in production workflows, enterprise technology and venture banking. Its initial Fund I portfolio includes space robotics, advertising decision software, video training-data infrastructure and fan-content platforms.

3C AGI Partners is a venture investment manager focused on the infrastructure that enables artificial intelligence. It backs founders developing computing hardware, memory, photonics, energy systems and other physical or architectural technologies needed to make AI more efficient and sustainable. The firm combines patient capital with AI, engineering and capital-markets expertise. Its Hercules Fund uses a mix of early-stage and later-stage investments and has funded five companies, including Cerebras. Its stated opportunity areas also include specialized AI processors, CPU architectures, space-based data centers and nuclear energy.

EndLyz Therapeutics develops small-molecule modulators of ATP13A2 and ATP10B lysosomal transporters for Parkinson's disease and other neurodegenerative disorders. Founded in2021 by SV Health Investors' Dementia Discovery Fund, the company aims to restore endo-lysosomal function; its initial development focus includes genetic Parkinson's subsets. Its March31,2025 launch announced an exclusive collaboration with KU Leuven researcher and scientific co-founder Peter Vangheluwe, with Quantum AI supporting drug-discovery research. Research goals and planned IND-enabling studies are not claims of clinical efficacy or regulatory approval. The current public directory names six scientific/operating leaders and five board affiliations across ten unique people, led by CEO and co-founder Joanna Wolak. US SEC filings identify Endlyz Therapeutics Inc., Delaware, CIK1875514. The July2021 filing reported USD3.25M equity sold toward a USD6.5M offering; this is an interim snapshot, not proof of final capital. The May2026 filing for a distinct March2026 offering reports USD17,250,395 sold, explicitly including conversions of earlier securities, so new cash cannot be equated to that total. The issuer describes Seed2 financing in2026 without a separately verified cash amount here. March2025 issuer disclosures identify USD2.2M MichaelJFoxFoundation programme funding; paid-to-date and instrument details remain unverified. Published backers include DDF, OxfordScienceEnterprises, AbbVieVentures, Parkinson'sUK and KU Leuven CD3; publication alone does not allocate them to a specific priced event. Current employee completeness and all private investor allocations remain unverified.

Donmienne Leung is listed by EndLyz Therapeutics as Board Member; AbbVie Ventures Representative. Published current affiliation reviewed October8,2026; exact appointment day is not established. Donmienne Leung is published in AbbVie’s venture team as Director II, Head of AbbVie Ventures Europe. Drug-discovery scientist with preclinical small-molecule and biologics development experience.

Floriana Licitra is listed by EndLyz Therapeutics as Director, Research Biology. Published current affiliation reviewed October8,2026; exact appointment day is not established.

John Davis is listed by EndLyz Therapeutics as Scientific Co-Founder. Published current affiliation reviewed October8,2026; exact appointment day is not established. John Davis is a published External Drug Discovery Adviser with the Parkinson’s Research Ventures programme. Own biography: John Davis is Professor of Pharmaceutical Discovery in the Nuffield Department of Medicine, University of Oxford, and a principal investigator within the Centre for Medicines Discovery.  As director of business development for the Alzheimer’s Research UK Drug Discovery Alliance (ARUK DDA), John is focused on building partnerships that capitalise on the strengths of the 3 drug discovery institutes within the ARUK DDA. In 2015, John joined the University of Oxford to establish the ARUK Oxford Drug Discovery Institute. The institute has developed a portfolio of early drug discovery programmes for Alzheimer’s and Parkinson’s, with an emphasis on genetically validated targets, and has forged multiple industrial alliances to accelerate project progression. John has 30 years of drug discovery expertise and has helped steer a number of drug candidates into development. The adviser/operating affiliation is distinct from a statutory directorship or personal cash check.

Oscar Barba is listed by EndLyz Therapeutics as Head of Discovery. Published current affiliation reviewed October8,2026; exact appointment day is not established.

Peter Vangheluwe is listed by EndLyz Therapeutics as Scientific Co-Founder. Published current affiliation reviewed October8,2026; exact appointment day is not established.

Richard Wade-Martins is listed by EndLyz Therapeutics as Scientific Co-Founder. Published current affiliation reviewed October8,2026; exact appointment day is not established.

Tim Edwards is listed by EndLyz Therapeutics as Independent Chairperson. Published current affiliation reviewed October8,2026; exact appointment day is not established.

Patrick Trojer chairs Booster’s board, appointed at theOctober10,2024launch. RA’s own advisor biography describes TRIANA president/CEO service from2021, prior Constellation co-founder/CSO work, NYUMedicalSchool epigenetics postdoctoral research and Innsbruck biochemistry/molecularbiologyPhD. Outsidepositions are careercontext, not personalcashchecks. Current source-verified RA affiliation: Patrick Trojer holds the source-published role of Advisor within RA Capital Management’s Raven group. Published academic qualifications: PhD. Universities identified in the own biography: Leopold-Franzens University, Innsbruck. This affiliation supports the firm’s healthcare research, investment, company-building, planetary-health or operational work according to the stated group. Published adviser and venture-partner titles retain their scope and do not imply employment or a general-partner appointment. Specific personal checks are not inferred from affiliation.

Aldemar Degroot is Booster’s publicly named strategic advisor. NMDPharma’s current own directory and2026BIO announcement also identify him as VPBusinessDevelopment. Booster does not publish a detailed career/education biography, so unsupported degrees or prior-employer histories are omitted. Additional primary career biography from RayaTherapeutic identifies business-advisor experience in international licensing, collaborations and investment acrossneuroscience/immunology/rarediseases, biotechcompanyco-founding and Novoentrepreneur-in-residenceexperience. These are publishedcareercontext, not assertedcurrentNovoemployment or personalcashchecks. Exactdoctoralinstitution/fullemploymentdates are unverified.

João Ribas serves as Booster’s interimCBO and board member. Novo’s current own biography identifies Partner inSeedInvestments, joined2018, and company-building/interimoperating experience. He previously worked atM Ventures and earned a CoimbraPhD with HarvardMedicalSchool/Brighamresearch. The2024BoosterPrincipal label is historical; currentPartner follows own managerdirectory. João Ribas joined Seed Investments in 2018, focusing on early-stage investments and venture creation. He currently holds several board positions and has led investments in companies like Asgard Therapeutics, Tribune Therapeutics, and Orbis Medicines. João often combines his investment role with interim operational responsibilities in portfolio companies. Prior to Novo Holdings, he was a Fellow at M Ventures (corporate VC of Merck KGaA), involved in the entire investment process including deal sourcing, investment selection, and due diligence. Before this, João founded new ventures in the U.S. and Europe, earning several entrepreneurial awards. During his Ph.D., he was part of MIT Hacking Medicine and led a non-profit organization in the U.S. João earned his Ph.D. from the University of Coimbra, conducting research at Harvard Medical School and Brigham and Women’s Hospital. He regularly creates content on biotech innovation, venture creation, and entrepreneurship.

Sonia M.Poli is BoosterTherapeutics head oftranslational sciences, a pharmaceuticalR&Dexecutive andboarddirector with25+years of internationalexperience. She earned anindustrialchemistryPhD fromMilan andcompletedCNRSParis postdoctoraltraining. Herpublishedgrantorbiography describes formerCSO/VPpositions atAddex,ACImmune,Minoryx andSibylla coveringnonclinicaldevelopment,CMC,regulatory andearlyclinical programs. Sheconsultedformorethan10biotechnologycompanies andhas50+scientificpublications. Her currentBoosterrole andauthenticportrait areverifiedownissuer; Sibyllatitles are historical ratherthan assertedcurrent fromanolderdirectory. The exactgrantorSoniaM.Poli naming corroborates thesame scientist.

Darci Trader is Booster’s scientific co-founder/advisor and an associate professor of pharmaceutical sciences at UC Irvine. Her research develops chemical tools to monitor and manipulate proteasome activity. Her chemistryPhD is from IndianaUniversity, followed by Scripps postdoctoral research; prior Purdue faculty service is historical, not her current institution.

Diogo Feleciano is Booster’s co-founder and CSO, leading its proteasome-activation research since its2020inception. His own grantor biography records a biochemistry degree from Coimbra, biochemistryPhD from FreieUniversitätBerlin, earlier ImperialCollege ocular research and entrepreneur-in-residence work at Apollo from2019.

Emanuele Gabellieri leads medicinal chemistry at Booster Therapeutics, serving since2020 according to the grantor’s own researcher profile. He earned a pharmaceutical chemistryPhD from theUniversityofSiena and began atSienaBiotech in2007, developingBACE1inhibitors. Following organicprocesschemistry work, he joinedACImmune in2013, contributing toTauPET diagnosticPI-2620 andTauaggregation inhibitorACI-3024 discovery. From2019he led neuroinflammatory NLRP3research. Externalprogram clinical phases andregulatorymentions are historicalcareercontext fromthepublishedprofile, not approvalorclinicalbenefit ofBooster’s ownproteasomecandidates.

Booster Therapeutics GmbH is a Berlin biotechnology company developing small molecules that directly activate20Sproteasomes, the cellular protein quality-control machinery, with an initial focus on neurodegenerative proteinopathies including Parkinson’s and Alzheimer’s disease. Its DGRADX platform combines automated high-throughput screening, structural methods including X-ray crystallography and computational tools; machine learning is not independently verified, so it is not taggedAI solely from computational branding. Direct proteasome activation is distinguished from lysosomal degradation and ubiquitin-directed26Sproteasome mechanisms. Its stated therapeutic effects are investigational research hypotheses, not established human clinical benefit or regulatory approval. The founder’s own MJFF biography dates inception to2020; the public launch and actualUSD15Mseedfinancing were October10,2024. Scientific founders are Diogo Feleciano and Darci Trader, alongside Apollo’s venture-creation platform. Exact legal disclosure identifies BoosterTherapeuticsGmbH, HRB220166, AmtsgerichtCharlottenburg. Its public directory names seven scientific/operating/advisory people and four board members with one overlap. A2025USD5Mresearchgrant award is separately qualified because paid-to-date/disbursement evidence is not published.

Durin’s own2026 company update identifies Dennis Hutchison as representing Durin Life Sciences at AD/PD2026 and contributing to discussions of earlier neurological disease detection. The source does not specify a current officer title or exact employment dates; a chief commercial or strategy title is not inferred.

Cassandra DeMarshall, PhD, is named by Durin’s own AD/PD2026 conference update as the research lead for its poster on a blood-based autoantibody Parkinson’s test. She is also a coauthor of the2011 original Durin-associated autoantibody research. This published research affiliation does not invent a current statutory director or officer appointment. Rowan University’s Spring2024 research magazine, printedpage28, explicitly names Cassandra DeMarshall, PhD, Durin’s director of research and a Graduate School of Biological Sciences alumna. This published title complements Durin’s own2026 Parkinson’s research-lead affiliation; benchmark claims remain attributed to researchers, not independently validated performance.

Mert Sahin, PhD, was appointed CEO of Durin Technologies in a November22,2023 issuer release and signed its March2025 equity amendment as CEO. He led the business during the2023 funding announcement. The July2025 SEC amendment instead names Maribeth Bluyus CEO; exact employment end date is unknown. No current Durin CEO appointment or personal investment is inferred.

Durin Life Sciences, Inc., formerly Durin Technologies, Inc., is a neurodiagnostics company founded in2010 and based in Stratford, New Jersey. Its Duritect blood-test platform combines disease-associated autoantibody biomarkers and machine-learning risk-score analysis for research and early detection of Alzheimer’s and Parkinson’s disease. Its own published science describes a CLIA-certified, CAP-accredited laboratory and peer-reviewed biomarker studies; these statements do not establish FDA approval or an independently validated clinical screening indication. Founder Robert Nagele’s Rowan University research underpins the autoantibody approach. Publicly disclosed private financing comprises three distinct SEC offerings:2019 equity,2021 equity subsequently amended through March2025, and2023 debt amended through July2025. Amendments update cumulative amounts sold within the same offering and are not extra funding rounds. The same SEC CIK1797306 confirms the former/current legal names; latest July2025 disclosure identifies Delaware jurisdiction, whereas older filings identified New Jersey. On May12,2026 NeuroVision Imaging announced it acquired Durin Life Sciences; consideration, payment form and exact legal closing day were undisclosed. The combined business operates as NeuroVision under CEO Steven Verdooner. Durin’s current public science website retains its brand, but a complete post-acquisition employee directory and standalone officer roster are not published. Historical CEO/director affiliations are dated to their original filings and are not automatically current employment. The unrelated Durin mining-robotics startup at durin.com and its protected2025 financing are distinct and preserved.

Benjamin A. Belinka Jr. is identified as Durin’s chief executive in the2019 and2021 SEC filings and January2023 amendment. The2011 original research paper discloses his salaried executive and stock ownership. Subsequent issuer and SEC disclosures identify different chief executives; this is a historical affiliation, not current post-acquisition leadership.

Robert Nagele is Durin’s founder and a researcher of autoantibody biomarkers for neurodegenerative disease. The2011 original PLOS paper discloses his founder ownership;2019–2025 SEC filings name him a director. Durin’s own2026 company profile continues to identify him as an employee. Exact current corporate officer title after the announced NeuroVision acquisition is not independently established. Rowan University’s Spring2024 research magazine, printedpage28, explicitly identifies Robert Nagele as founder and chief scientific officer of Durin Technologies and professor of geriatrics and gerontology at Rowan-Virtua SOM. This is the published2024 title, not independent confirmation of a post-acquisition legal officer appointment.

Lauren Schwartz is a published general partner of 20SALES, focused on enterprise, strategic sales, deal negotiation. The official fund directory highlights operating experience associated with Twilio, Fivetran, Google. These career references describe expertise rather than additional inferred current employment.

Renu Gupta is a published general partner of 20SALES, focused on plg, strategic, large enterprise, operations. The official fund directory highlights operating experience associated with Pachama, dropbox, Slack. These career references describe expertise rather than additional inferred current employment.

Kim Graves is a published general partner of 20SALES, focused on smb, mid market, outbound, plg. The official fund directory highlights operating experience associated with Salesforce, Slack. These career references describe expertise rather than additional inferred current employment.

Liat Bycel is a published general partner of 20SALES, focused on smb through enterprise, plg, cs, sales dev. The official fund directory highlights operating experience associated with Airtable, Twitter. These career references describe expertise rather than additional inferred current employment.

Kelly Bray is a published general partner of 20SALES, focused on cs, renewals, retention. The official fund directory highlights operating experience associated with Mongo DB, Slack, Box. These career references describe expertise rather than additional inferred current employment.

Jessica Arnold is a published general partner of 20SALES, focused on sales dev, smb, field marketing. The official fund directory highlights operating experience associated with Amplitude, Salesforce, dropbox. These career references describe expertise rather than additional inferred current employment.

Foliumtec GmbH is an Austrian materials-engineering and business-development company focused on lightweight, multifunctional components. It works on materials and manufacturing approaches for thinner, lighter and more functional products, including composite materials for consumer-electronics acoustics. Its published collaboration with 4a manufacturing covers micro-sandwich acoustic materials marketed under the CIMERA brand, alongside other lightweight material applications. Founded in 2018 and led by materials engineer Domenico Foglia, Foliumtec also supports technical, sales and operational work at micro-manufacturing company NanoVoxel and is a registered shareholder in that business. It is an operating engineering company rather than a venture-fund manager.

4a technology GmbH is the Austrian parent company of the 4a engineering group, based in Traboch. The group develops technologies based on polymer materials, composites, lightweight construction and mechatronics for sustainable mobility, communications and vehicle safety. Its distinct operating businesses develop lightweight acoustic and structural sandwich materials, thin foam sheets and antenna radomes; robotic platforms and realistic targets for testing driver-assistance systems and autonomous driving; and materials-testing equipment, simulation services and software for characterizing materials and batteries. The parent company provides the group’s technology and corporate structure and is a registered shareholder in NanoVoxel, a separate precision micro-manufacturing company. Established in 2002, it is an operating technology group parent rather than an investment-fund manager.

Mechanical and acoustic engineer named on Foliumtec’s own team page as supporting Foliumtec and NanoVoxel in technical, sales and operational activities.

Investment associate with finance, economics and accounting studies atRockhurst and prior early-stage diligence experience with University Venture Fund Crossroads.

Board member with energy-transition, mobility and venture investment experience. Own biography identifies Energy Impact Partners as outside employment, not a KCRise operating title.

Bernard Majoie (1939–2021) was a pharmaceutical research executive and entrepreneurial philanthropist. He spent more than35 years developing Laboratoires Fournier’s research activities and founded the Fournier-Majoie Foundation in2006 with part of his personal wealth. He chaired it for more than a decade before passing the presidency to his son Jérôme. reMYND’s2018 financing announcement explicitly names Dr Bernard Majoie as an existing shareholder participating in its round; this personal attribution is retained separately from the foundation and does not imply that the foundation was the subscriber. His photograph and death are documented in the foundation’s own2021 memorial.

Board member with institutional investment and endowment management experience. Outside foundation investment titles are distinct from this KCRise board role.

Founded KCRise in 2016 after identifying a regional technology funding gap through KCRising; prior wealth-management career at Merrill Lynch.

Venture and private equity professional with prior OCA Ventures finance and investment diligence experience; own biography also uses Ed Frindt.

Board member with telecommunications, entrepreneurial and early-stage investment experience; own biography also uses Ron LeMay.

Ana Katsafanas was publicly listed as Senior Venture Associate in the browser-cached own Foundation Venture Capital Group staff directory. The live native directory downloaded October8,2026 omits this name, so this record is qualified as historical or last-published affiliation rather than verified current employment. Exact start and departure days, a detailed personal biography and an authentic named portrait are undisclosed. The affiliation concerns institutional venture work, not a personal investment.

Danielle Kozlosky was publicly listed as Venture Associate in the browser-cached own Foundation Venture Capital Group staff directory. The live native directory downloaded October8,2026 omits this name, so this record is qualified as historical or last-published affiliation rather than verified current employment. Exact start and departure days, a detailed personal biography and an authentic named portrait are undisclosed. The affiliation concerns institutional venture work, not a personal investment.

Jocelyn Mathew was publicly listed as Venture Associate in the browser-cached own Foundation Venture Capital Group staff directory. The live native directory downloaded October8,2026 omits this name, so this record is qualified as historical or last-published affiliation rather than verified current employment. Exact start and departure days, a detailed personal biography and an authentic named portrait are undisclosed. The affiliation concerns institutional venture work, not a personal investment.

Amir Rustamzadeh is a partner at Firestreak Ventures, backing founders in developer tools, infrastructure, open source, data, AI/ML and cybersecurity. His April2026 interview describes robotics and Jet Propulsion Laboratory experience, building a software business, and developer-experience work as an early Cypress employee. His professional public profiles also describe prior product leadership at Kurtosis. His own GitHub identity links the same professional LinkedIn handle and lists Firestreak affiliation.

Walter G. Kortschak founded Firestreak Ventures and invests in early-stage AI, machine-learning infrastructure, developer tools and cybersecurity. Summit Partners’ biography names him a senior adviser and former managing director, with venture experience beginning at Crosspoint before joining Summit in1989. He helped launch SignalFire in2013 and transitioned from executive chairman/CIO to chairman emeritus in2023. He holds engineering degrees from Oregon State University and Caltech and an MBA from UCLA, and serves as a Caltech trustee. His Firestreak profile emphasizes patient first-check investing; past institutional and personal investments remain distinct.

Aggie Worthington is current vice president and CFO in FVCG’s own management-and-staff roster and the related NewJerseyHealthFoundation directory. The financial-officer affiliation is verified; no undocumented professional credentials, employment starting date, personal investment or more extensive career history is inferred. Current directories publish no authentic named portrait.

Jeannine Hodkey is current program and finance administrator in the own FVCG staff roster; the related NewJerseyHealthFoundation directory uses the same substantive title. The role concerns the foundation family’s funding and research-support institution, but precise personal duties and earlier jobs are undisclosed. No starting day or cash check is invented.

Laura Harrel is a vice president in the current own FVCG management roster, also named by the related NewJerseyHealthFoundation’s current directory. The institution supports early health-research commercialization and start-up funding; a more detailed individual career biography and authentic named photograph were not available from those native directories. Her published manager affiliation does not imply personal financing.

Michael (Mike) Wiley is a current published FVCG vice president and also works with the NewJerseyHealthFoundation family. His own public profile corroborates involvement in UpstreamAccess and ZenaTherapeutics commercialization and earlier NewJerseyEconomicDevelopmentAuthority work. He is distinct from authors, sportspeople and a UNMC scientist with the same name. Institutional portfolio work is not a personal cash investment.

George F. Heinrich MD is memorialized in FVCG’s current own leadership page as vice chair emeritus, with life dates1945–2025. Earlier foundation and university releases identify his leadership in medical innovation and admissions at RutgersNewJerseyMedicalSchool. Rutgers2026governing-board materials confirm the late educator’s memorial professorship. This is an explicitly historical/memorial affiliation, not currentemployment; an exact departure day is not inferred from year-only own biography.

James M. (Jim) Golubieski is current president and CEO of FVCG, NewJerseyHealthFoundation and FoundationforHealthAdvancement, and also a published FVCG director. BioNJ’s2026 own biography describes more than45 years in finance and strategic leadership. Earlier positions included ArrayMedical CFO, leadership of Glendale banking/investment companies, and KPMG audit management. His published operating-company boards do not prove personal financing tickets.

Marc Heinrich is an attorney and current published FVCG board director. The manager directory describes his external position as senior adviser for policy and planning in the NewYorkCityMayor’sOffice; a primary2024 CharterRevisionCommission report corroborates that historical municipal affiliation. This dated2024 employer role is not independently asserted unchanged in2026. His institutional board position does not identify a personal investment.

Navneet Puri is a current published FVCG director and pharmaceutical entrepreneur, identified by FVCG as Nevakar founder/board member. His own2026 public update explains a transition from operating founder/CEO to strategic adviser; older employer bios calling him currentCEO are therefore qualified historical. His prior development work included Baxter and Amgen, and he founded InnoPharma, acquired byPfizer2014. The FVCG directorrole does not establish a personal cash check.

Robert W. Pierce II is a director in FVCG’s current own leadership roster, which describes his professional affiliation as head of business development and strategy at SiemensHealthineers. The listed governance role supports the foundation-affiliated health-technology investment institution. No additional career history, precise appointment date or personal cash check is invented from that directory entry.

Susan J. Flynn-Hollander is treasurer of FVCG’s current own board of directors. SetonHallLaw’s own faculty directory identifies the same full-named attorney as ethics training officer of the NewJerseyStateEthicsCommission and provides her authentic photograph. The external directory affiliation is source-qualified rather than a guessed FVCG employment responsibility. No personal investment is inferred.

Sandra Brown Sherman is secretary of FVCG’s current published board and a tax/trusts-and-estates attorney. Her own law-firm page currently labels her OfCounsel, while FVCG retains the older Partner description; the newer employer title prevails in this biography. She co-founded ShermanAtlas in2014 and has worked in estate/charitable planning and family-held business matters. Her institutional board role is separate from personal investing.

Roger S. Fine is chair of Foundation Venture Capital Group’s current published board. His own WindhamCapitalPartners biography confirms the same FVCG chair identity and earlier thirty-year Johnson&Johnson career, ending as corporate vice president and general counsel. His education is ColumbiaUniversity and NewYorkUniversitySchoolofLaw. Undated other-foundation chair titles are not automatically asserted current, and board service does not constitute a personal cash check.

Foundation Venture Capital Group, LLC (FVCG) is a Princeton, New Jersey health-technology impact investor affiliated with New Jersey Health Foundation and Foundation for Health Advancement. The own native logo names the exact LLC and its New Jersey Health Foundation affiliation; US trademark records independently identify that legal company. Rutgers primary2009/2012 publications establish a2006 inception, while the company LinkedIn metadata says2005; no exact founding day is asserted. It supplies pre-seed and seed financing and strategic, operational and back-office support to university and healthcare research spin-outs at affiliated New Jersey institutions. Investment gains support further research and innovation. It is distinct from the unrelated Foundation Capital VC and from its separately named affiliated foundations; a LinkedIn nonprofit category is not treated as independent proof of the LLC tax classification. Neuroscience relevance is directly supported by historical Durin neurodegenerative-disease diagnostics, MentiNova Parkinson’s dyskinesia drug research and Zena anxiety/addiction therapeutics; digital-pathology and medical-device holdings also support deep-technology relevance. These research descriptions do not establish regulatory approvals, clinical efficacy or AI models for every company. The current native directory lists five staff and seven living directors, plus George F.Heinrich as memorial vice-chair emeritus (1945–2025). Three venture associates retained in an older browser-cached version but absent from the current downloaded roster are separately marked historical/last-published, with no inferred precise departure dates. Rutgers2012 reports an initial USD5million allocation from NJHF’s endowment to support the separate venture organization; this is historical institutional capitalization, not an external LP fund close, current AUM or a distinct registered pooled fund. Published up-to500K early investment commitments and newer1M company commitments are not automatically actual paid tickets. The portfolio explicitly identifies Durin, Longevica and Visikol as exited through equity sales; a disposal is not a fresh financing or proof of continuing ownership. No successor entity or fund vehicle is inferred from shared board/staff. New Jersey Health Foundation’s own January31,2013 release independently confirms that FVCG was established in2006 with an initial USD5million from NJHF and announces board approval of an additional USD5million investment allocation. The latter is an approved institutional allocation, not a verified new externally subscribed LP fund, actual fully drawn cash, currentAUM or company fundraising. That release’s nine historical portfolio entries also identify spinal-cord-injury cell research, cancer biomarkers and drug-discovery companies absent from the current portfolio page. The older Rutgers2012 capitalization PDF remains browser-indexed but its direct original URL now returns404; the accessible parent-issued2013 source corroborates the amount and year.

Superlinked co-founder and COO, focused on commercial development and scalable AI infrastructure. A former software engineer and digital-strategy consultant at McKinsey in London, with a London Business School MBA. His own Forbes Technology Council member profile describes helping AI-native companies scale reliable, cost-efficient systems; his company identifies his COO role and public talks on enterprise LLM deployment. The authentic portrait is his own named council-member avatar.

Superlinked co-founder and CEO, building vector-compute and open-source inference infrastructure. Previously a machine-learning engineer at Google and YouTube, developing infrastructure for YouTube Ads and user-behavior prediction. His own company and original Index investor announcement describe his work on enterprise-scale embeddings, retrieval and machine-learning systems. His named conference portrait is authentic; no inferred current positions at prior employers are added.

Chris McFarlane is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Director (latest public state filing). FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred.

Peggy Grant is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Director (latest public state filing). FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred.

Jay Jacob is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Director. FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred. His own Community Capital Holdings biography explicitly corroborates current membership of the FCHN (Memorial Foundation) board. The state report reverses his name as Jay, Jacob; primary self/company biography establishes Jay Jacob. Tax-data spelling Jay Jacobs is retained only as a source variant.

Bruce Keir is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Director (latest public state filing). FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred.

Linda Cooke is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Vice Chair, Secretary and Treasurer (latest public state filing). FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred.

Paul Sallwasser is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Chief Executive Officer. FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred. The March2021 HSIC partner announcement and state insurance examination also independently identify him as FCHN CEO. An authentic accessible portrait remains unverified.

Shane Strum is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Director (latest public state filing). FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred. Memorial’s September3,2026 primary announcement identifies him as its permanent President and CEO following interim service sinceSeptember2024; that operating role is separate from his FCHN director affiliation.

Florida Community Health Network Corp. (FCHN) is a Florida nonprofit investment corporation established in 2012 as a wholly owned subsidiary of Memorial Foundation, supporting Memorial Healthcare System and residents of the South Broward Hospital District. Its active Florida registration is N12000009820 and its EIN is 46-1405669, distinct from the inactive Florida Community Health Network, Inc. registration N12000002590. FCHN invests in healthcare ventures and providers to improve access, efficiency and cost of care, including healthcare operating joint ventures and digital health innovation. A March 2021 primary announcement confirms its Health System Innovation Council alliance with Caduceus Capital Partners, linking health-system priorities with early-stage technology sourcing and clinical adoption. This alliance is not an independently verified FCHN managed LP fund or a disclosed cash investment into Caduceus. FCHN is named in Tombot’s June 2026 Series A3 financing supporting companion robotics for aging and cognitive or behavioral health markets; company product intentions are not proof of clinical efficacy. Paul Sallwasser is its CEO, with governance recorded from the latest accessible April 2025 state annual report. Memorial Foundation, Memorial Healthcare System, Florida Funders, Florida Association of Community Health Centers and other similarly named networks remain separate. No authentic standalone FCHN logo or independent public website was verified; the image remains an explicit research gap rather than using a parent or partner mark.

Steve Einhorn is listed in Florida Community Health Network Corp.’s latest accessible April2025 public state annual report as Chairman (latest public state filing). FCHN is the nonprofit investment subsidiary of Memorial Foundation, serving Memorial Healthcare System and the South Broward Hospital District. The filing verifies this governance affiliation; no personal investment or exact appointment day is inferred.

Joris Winderickx is a KU Leuven emeritus biologist whose work on humanized yeast contributed to the creation of reMYND and ADx NeuroSciences. In KU Leuven’s September2026 interview, he says he left reMYND’s founding board after about six years but remains a scientific adviser.

Johan Cardoen chaired reMYND’s board after his appointment in September2024. The company announced his death in December2025. He previously led VIB’s innovation activities and was CEO of CropDesign before its2006 acquisition by BASF.

Steven Winderickx serves on reMYND’s board and is identified by the company as an investor at Maatschap Winstock. No personal check, amount or financing date is inferred from that board biography.

Emiel Michiels is a board member of reMYND. Its directory identifies him as Investment Manager Healthy Living at Korys; this affiliation is distinct from a personal financing participation. Emiel Michiels is listed by Korys as Investment Manager. He invests in life sciences, drawing on doctoral work in structural and molecular biology with a neurobiology focus. Before Korys he helped develop scientific spin-offs as an entrepreneur in residence at VIB.

Paul Van Dun is a reMYND board member. The company identifies his outside role as CEO of KU Leuven Research & Development; KU Leuven’s Joris Winderickx interview also describes his support of the original spin-off board.

Rudy Dekeyser is an independent member of reMYND’s current board. The company’s2018 financing announcement also named him as a director.

Tine Bekaert serves on reMYND’s board and is a Senior Investment Manager at PMV, independently confirmed by PMV’s own reMYND portfolio page. Tine Bekaert is published in PMV’s current public directory as Senior Investment Manager. This is the specific publicly documented professional or governance affiliation, including any named related unit; no personal cash investment or exact start date is inferred.

Goedele Ertveldt is a reMYND board member. The company identifies her outside affiliation as investment manager at SFPIM; board service alone does not establish an individual investment. Goedele Ertveldt is published by SFPIM with these professional/governance affiliations: Investment Manager — Operating team. Operating team employment is distinguished from governance and committee oversight. No personal investment is inferred.

Sara Lambrechts is Head of Finance at reMYND, as named in the company’s current public leadership directory.

Nancy Van Osselaer is reMYND’s development adviser, supporting the company’s investigational neurodegenerative-disease programmes.

Chris Freitag is a physician and clinical adviser to reMYND, as published in its current leadership directory.

Gerard Griffioen is Chief Scientific Officer of reMYND. He leads its neuroscience drug-development science and is the named investigator for ADDF’s REM392 Alzheimer’s clinical project.

Floor Stam is CEO and a board member of reMYND, appointed CEO in September2024. A neurobiologist trained at Vrije Universiteit Amsterdam and the Salk Institute, she co-founded Flamingo Therapeutics and previously commercialized technologies at VIB.

reMYND NV is a clinical-stage Belgian biotechnology company developing oral small molecules for neurodegenerative diseases. Founded in 2002 as a KU Leuven spin-off, it is registered under Belgian enterprise number BE0476.910.101 and is based at Gaston Geenslaan 1, Leuven. Its Alzheimer’s programme investigates septin modulation to restore calcium homeostasis and synaptic function. Lead candidate REM392 is investigational; the September2026 announcement plans a Phase1b patient study for early2027. Earlier REM127 Phase2a findings and exploratory AI digital-twin analyses do not establish approval or a proven cure. The Huntington’s candidate REM949 and mitochondrial-dysfunction discovery work remain development programmes. In March2025, reMYND sold its contract-research business to InnoSer to focus on proprietary drug development; older homepage CRO text is superseded by that transaction announcement. CEO Floor Stam was appointed in September2024; Gerard Griffioen is CSO. The current public directory names five operating leaders/advisers and seven board members, with Floor appearing in both groups. Former chair Johan Cardoen died in2025. KU Leuven’s September2026 interview separately confirms Joris Winderickx remains a scientific adviser after leaving the founding board. Completed announced equity comprises EUR12M SeriesB in December2018 and an additional EUR12M second close announced January21,2021; EUR24M is their aggregate, not a third raise. Investor PMV also documents an earlier convertible loan and a2022 syndicate financing with undisclosed amounts. On September21,2026, the company announced EUR3.5M strategic support from ADDF for REM392; ADDF project20731238 reports USD4,122,340 funding over September15,2026–March15,2028. These are source-specific representations of one programme award, not two cash raises. Instrument, disbursement and paid equity are unpublished, so structured cash amounts remain unknown. VLAIO/IWT and Michael J. Fox Foundation historical grant support is documented separately from equity; unspecified grant totals, license payments and the CRO sale price are not invented. BNP Paribas Fortis Private Equity’s own original credentials separately document two earlier equity investments inSeptember2009 andMay2016, corroborating the current bank portfolio’s2009 entry. These historical financings have undisclosed company totals, individual tickets, exact closing/announcement days and priced-series stages. They are distinct from the later2018 and2021 SeriesB closes; no parentbank, subsidiary or advisor-only cash duplication is inferred. The official ARKimedes-Fonds year-end2009 report additionally identifies Fortis Private Equity Arkimedes as the historical investing vehicle and records EUR750,000 cumulative investments in reMYND through December31,2009. This cumulative portfolio history is not assigned as the individual September2009 check or a further company round.

Biotechnology entrepreneur, co-founder and former president and CEO of Zymeworks, with expertise in protein engineering and biologics development.

Life-sciences investor and biotechnology business-development executive with previous roles at Chinook Therapeutics and Sierra Oncology.

Amplitude co-founder and biotechnology company builder, trained in immunology and formerly on BDC Capital’s Healthcare Venture Fund investment team.

Biotechnology analyst with doctoral research in lipid-nanoparticle delivery and engineered platelets for cell therapy; previously an Amplitude fellow.

Amplitude co-founder and managing partner; formerly led BDC Capital’s Healthcare Venture Fund and was a founding managing director of Physic Ventures.

Healthcare investor and immunology scientist; formerly vice president of investment banking at Bloom Burton & Co.

Biotechnology investor and biochemistry scientist with prior business-development roles at IntelGenx, Genome Québec and Mitacs.

Marketing and communications professional leading Amplitude’s brand communications, creative assets and events; previously worked at Bloom Burton & Co.

Finance executive overseeing Amplitude’s accounting, investor reporting, legal support, valuation and portfolio analysis; previously director of finance at CoPower.

Biotechnology company builder and investor; also managing director of Pre-Amp, Amplitude’s internal discovery and incubation engine. Formerly built platform companies at Flagship Pioneering.

Healthcare investor with experience in early-stage therapeutics, medical devices, digital health and B2B SaaS investing.

Finance and accounting executive supporting biotech incubation and growth; previously controller at CellCarta Biosciences and auditor at EY Montreal.

Life-sciences venture investor and company builder; formerly a Ventures West partner and co-founder and president of CNS-focused MSI Methylation Sciences.

Gaianixx is a University of Tokyo spinout developing and manufacturing semiconductor materials. Its proprietary Multi-functional interlayer and dynamic lattice-matching process allow high-quality single-crystal thin films to grow across materials with different crystal structures, addressing defects and cost constraints in compound semiconductors. Its materials target sensors, power electronics, communications filters, LEDs and optical devices. The company operates a technical center and pilot production line in Yamanashi to supply samples and validate manufacturing processes with device makers.

Joined Gaianixx in April 2023. His background includes high-power LED commercialization for automotive manufacturers and Japanese market development for 3D lidar technology.

Joined Gaianixx in December 2023. His experience includes sputtering processes, functional thin-film materials, production equipment, technology marketing and business strategy at a vacuum-technology manufacturer.

Co-founded Gaianixx in 2021 and became CEO in 2022. His background includes industrial machinery sales and international semiconductor business development across Japan, the United States, Europe, China and Southeast Asia.

Leads operations at Gaianixx after sales and business-development work in the automotive, semiconductor and industrial-machinery industries, including Japanese business leadership at a US semiconductor company.

Joined Gaianixx as chief manufacturing officer in April 2024. At Toyota he helped establish automotive semiconductor operations, developed semiconductor manufacturing processes and managed production-line launches.

Joined Gaianixx in April 2022 and works on technology development and materials evaluation. His previous research at Toshiba included inkjet heads and silicon-carbide power semiconductors; he holds an engineering doctorate from Tottori University.

Developed Gaianixx’s thin-film materials technology through research in functional ceramics and deposition equipment. He is a specially appointed researcher at the University of Tokyo and holds an engineering doctorate.

Leads finance and corporate functions at Gaianixx. His experience includes equity capital markets and underwriting at securities firms, followed by financial management and investor communications at a real-estate fund.

Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Healthcare Staffing. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Precision Medicine. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Digital Health. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Hospital & Behavioral Health. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Payors & Health Systems. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Regulatory & Risk. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2023 Council of Strategic Advisors, advising on Ambulatory & Post-Acute Care. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Healthcare Strategy. Historical external council service is distinguished from current operating employment or investment partnership.

Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Health Innovation & Policy. Historical external council service is distinguished from current operating employment or investment partnership. Exact issuer advisoryannouncement identifies HarlanLevineMD, CityofHope PresidentHealthInnovationPolicy; currentgrid misspells surnameLavine. Authentic samephysicianportrait governs, no unrelated namesakemerge.

Published member of Wavemaker 360’s 2024 Council of Strategic Advisors, advising on Disruption & Technology. Historical external council service is distinguished from current operating employment or investment partnership.